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ABBREVIATIONS 
 
 
ATF      Artificial Transcription Factor 
BOC      Butossicarbonyl  
BTB      Bric-à-brac, Tramtrack and Broad  
CUL      Cullin  
DBD      DNA Binding Domain 
DCM      Dicloromethan  
DIPEA     Diisopropilethylammina  
DMF      Dimethylformammide 
EDT      Ethanedithiol 
ELISA     Enzyme-linked immunosorbent assay 
ESI      Electrospray Ionization-Mass Spectrometry  
FMOC     9-Fluorenilmetossicarbonyl  
HATU      2-(1H-9-Azobenzotriazole-1-yl)-1,1,3,3,- 
         tetramethyluronium  
HBTU      2-(1H-Benzotriazole-1-ile)-1,1,3,3- 
         tetramethyluronium  esafluoro phosphate  
Hh      Hedgehog  
HOBT      Hydroxybenzotriazole  
ITC      Isothermal Titration Calorimetry 
KCTD      K+ Channel Tetramerization Domain 
HSQC      Heteronuclear Single Quantum Coherence  
LC-MS     Liquid chromatography-mass spectrometry  
MeOH      Methanol  
NMP      N-Methyl-2-pyrrolidone  
NMR      Nuclear magnetic resonance spectroscopy  
NOE      Nuclear Overhauser Effect Spectroscopy  
OtBu      O-t-Butyl  
POZ      Poxvirus Zinc Finger  
PyBOP     Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
         hexafluorophosphate 
RP-HPLC     Reverse Phase High Performance Liquid 
         Chromatography  
TAD      Trans Activaction Domain 
tBu      t-Butyl  
TEV      Tobacco Etch Virus  
TFA      Trifluoroacetic acid 
TIS      TriisopropylSilane 
TRIS      Tris (hidroxy methyl) amino methane  
Trx      Thioredoxin A  
UV-Vis     Ultraviolet-Visible Spectroscopy  
VEGF      Vascular Endothelial Growth factor 
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SUMMARY 
 
 
The study of the protein-protein interactions (PPI) is fundamental to correlate 
structure and function in biological systems. The understanding of molecular features 
that regulate these interactions is the starting point for the design of specific ligands 
able to modulate main cellular activities allowing the development of new systems for 
biotechnology applications. 
Recent studies by Arora and co-workers highlighted that roughly 60% of the protein 
complexes found in the PDB display helical structure at interface such as α- and 310-
helices. The average length of helical domains in interacting interfaces is rather small 
and spans two to three helical turns (or eight to twelve residues). These complexes 
suggest that it may be possible to develop small molecules that mimic such structure 
domains and display functionality in a similar fashion. 
Peptides are molecules able to mimic structural motifs enabling the detailed analysis 
of the interaction at the level of individual amino acid residues. Moreover several 
progresses in chemical synthesis allowed the introduction of different building blocks 
and modification at peptide backbone, helpful to stabilize defined secondary 
structures. This can be used to design peptides and peptidomimetics, mimicking 
sequences involved in PPI as molecules of biotechnological interest.  
 
Malfunctions in transcriptional regulation are associated with many human diseases 
and there is considerable interest in biomedical and biotechnological field in 
developing artificial transcription factors (ATFs) that must minimally contain a DNA 
binding domain (DBD) and a transactivation domain (TAD).  
Designing artificial TADs is proven difficult because these systems interact with 
multiple target proteins as part of their normal function and, moreover, there are only 
a limited number of high-resolution structures of TADs in complex with target 
proteins. 
The p53 protein is a transcriptional activator factor with a fundamental role in cellular 
survival. Recent structural studies by Omichinski and co-workers gave insights into 
interaction between p53 TAD2 and tfb1/p62 subunit of the transcription factor TFIIH 
and contributed to the understanding of the way p53 protein works in transcriptional 
activation.  
On the basis of these information new molecules, able to interfere with the binding 
between p53 TAD2 and tfb1 of TFIIH, were designed. In our hypothesis peptide 
analogues of p53 TAD2 with enhanced helical propensity could yield a more potent 
artificial TAD. Therefore, several peptides mimicking the helical fragment 47-55 of 
p53 TAD2 were designed by using different molecular tools, such as N- and C-
capping boxes, and synthesized.  
A structural analysis of all obtained peptides by CD experiments highlighted an 
increased helical content relative to native p53-13 peptide and one of these peptides, 
E-Cap, showed a higher binding affinity than other peptides in ITC experiments.  
Furthermore NMR experiments were performed to elucidate how E-Cap peptide 
interacts with tfb1. NMR titrations spectra displayed that E-Cap peptide binds along 
the same interface of p5325-75, forming a 9-residue α-helix when in complex with tfb1. 
NMR studies of E-Cap peptide in complex demonstrated the presence of both the i, 
i+3 and the i, i+4 interactions for Leu6 with Leu9 and Trp10 residues, respectively.  
The potential ability of E-Cap peptide to activate transcription in vivo was investigated 
in yeast cells by activation assay of lacZ with LexA fusion peptide. E-Cap peptide 
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showed to be a more potent transcriptional activator than positive control Gal4, p53-
13 native sequence and AH and VP2 transcriptional activators.  
Besides mutation studies for E-Cap and p53-13 peptides provided evidence that both 
i, i+3 interaction between Leu6-Leu9, and i, i+4 interaction between Leu6-Trp10 have 
an important role for the in vivo activity. 
In conclusion, a new peptide with high content of helical conformation and able to 
activate transcription in vitro was designed using only proteinogenic amino acids. 
This result will be used to develop a new interesting biotechnological system such as 
"programmable ATF", linking obtained TAD to new synthetic DBD. 
 
 
BTB/POZ domain-containing proteins are identified in diverse cellular locations and 
participate in different processes ranging from transcriptional repression/activation to 
cytoskeletal organization. In particular, KCTD are a class of protein containing 
BTB/POZ domains with different biological function as KCTD11 that inhibits tumor 
growth in medulloblastoma. POZ/BTB domain of KCTD proteins mediates interaction 
with Cullin, a family of proteins ubiquitin ligases that induce proteolysis of target 
proteins by proteasome. Recently, different studies highlighted that several members 
of KCTD family protein bind to Cullin3 (Cul3).  
The understanding of the structural features required for the interaction of the Cul3 
with KCTDs is an intriguing challenge and is the basis for the future design of 
molecules with agonist/antagonist function for biotechnological applications. 
To achieve this goal the attention was focused on KCTD11 that mediates interaction 
with Cul3 by its POZ/BTB domain at N-terminus.  
Starting from the proposed model of KCTD11-Cul3 interaction, peptide molecules 
mimicking the helical fragment of Cul3 49-68, were designed. To evaluate the role of 
some aromatic residues of Cul3 in the interaction with KCTD11 two mutant peptides 
were developed (Cul3-KK and Cul3-Y(P)). Structural analysis by CD experiments 
highlighted that these peptide and Cul3-wt native sequence peptide are unfolded. 
ELISA assays showed that Cul3-KK and Cul3-Y(P) have a lower affinity than Cul3-wt 
for KCTD11. 
Subsequently, in order to test if the enhance of the helical propensity match with a 
gain in binding affinity, opportunely constrained sequences were designed and 
synthesized. Cul3 stapled peptide, with a hydrocarbon bridge in central position of 
sequence, showed indeed a higher helical structure than the native Cul3-wt peptide. 
Preliminary ELISA assays indicate that both Cul3-wt and Cul3 stapled peptides were 
able to interact with KCTD11.  
Future studies by ITC and NMR will allow the evaluation of the Kd and the molecular 
features governing the interaction with KCTD11 required for the future perspectives 
in biotechnology field. 
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RIASSUNTO 
 
PREMESSE SCIENTIFICHE 
 
Interazioni Proteina-Proteina e Peptidomimetici 
 
Le interazioni tra le proteine svolgono un ruolo chiave nella regolazione 
dell’omeostasi cellulare. La comprensione della relazione tra la struttura e la funzione 
è fondamentale per comprendere le basi molecolari di tali interazioni.  
Lo studio delle superfici d’interazione tra proteine, la cui struttura è stata risolta 
mediante tecniche NMR o raggi X e depositata nel PDB, ha evidenziato che in circa il 
60% dei casi sono presenti motivi elicoidali come α-eliche ed eliche 310. 
In particolare, è stato osservato che la lunghezza media delle eliche coinvolte nelle 
interazioni proteina-proteina è relativamente piccola e comprende in genere due o tre 
turn, cioè 8/12 residui. All'interno di queste brevi sequenze elicoidali sono contenuti i 
residui essenziali per l'interazione in quanto ognuno di questi contribuisce, 
interagendo con i residui dell’altra proteina, all'energia libera di legame.  
I peptidi sono potenzialmente molecole capaci di mimare le superfici di legame tra 
proteine e quindi di essere utilizzati per modulare importanti processi cellulari. 
Purtroppo, estrapolati dalle proteine, essi raramente conservano la conformazione 
nativa mentre adottano un insieme di strutture diverse, perdendo la capacità di 
legarsi specificamente ai loro bersagli. Inoltre, l’instabilità proteolitica dei peptidi è un 
altro fattore che ne limita l’utilizzo. Per questi motivi negli ultimi anni sono state 
sviluppate diverse metodologie per stabilizzare la struttura elicoidale di peptidi e per 
aumentare la loro resistenza alle proteasi.  
Queste strategie sono state utilizzate per ottenere molecole, derivate da domini 
coinvolti in interazioni tra proteine, quali ligandi specifici importanti per lo sviluppo di 
nuovi sistemi da utilizzare in ambito biotecnologico. 
 
 
p53: Un potente attivatore della trascrizione 
 
L’alterata regolazione della trascrizione è una delle principali cause di malattie 
umane. Per questo motivo c'è un notevole interesse nello sviluppo di fattori di 
trascrizione "artificiali" (ATF) che possano attivare o reprimere un gene specifico [6]. 
Affinché una biomolecola possa funzionare come ATF deve contenere un dominio di 
transattivazione della trascrizione (TAD) in grado di legare un fattore di trascrizione e 
un dominio di legame specifico al DNA (DBD).  
Mentre negli ultimi anni sono stati sviluppati diversi tipi di domini artificiali di legame 
al DNA come poliammidi pirrolo-imidazolo (PIP), PNA e proteine a dita di zinco, più 
complicato si è rivelata la progettazione di domini di trascrizione artificiali a causa 
delle scarse informazioni strutturali. 
Recentemente il gruppo del professor Omichinski dell'Università di Montreal in 
Canada ha risolto, mediante tecniche NMR, la struttura del complesso molecolare 
costituita dal dominio TAD della proteina p53 e il fattore di trascrizione generale 
TFIIH. 
La proteina p53 è un potente attivatore della trascrizione che agisce in seguito a 
danni alla cellula. I geni bersaglio di p53 sono diversi e possono mediare risposte 
cellulari differenti: arresto del ciclo cellulare nel punto di regolazione G1/S, 
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attivazione del sistema di riparazione del DNA e inizio della cascata di segnali che 
inducono l'apoptosi nel caso in cui il danno al DNA sia irreparabile. 
La struttura NMR del complesso tra il dominio tfb1 di TFIIH del lievito (p62 nell’uomo) 
e la sequenza di p5320-73 contenente il dominio TAD2, ha evidenziato che p53 
contiene una α-elica anfipatica tra la Pro47 e la Thr55 che interagisce con i foglietti 
β5-β7 ed il loop fra β5 e β6 del dominio PH della subunità tfb1 di TFIIH. Studi di 
mutagenesi sito diretta hanno dimostrato che i tre residui idrofobici Phe54, Trp53 e 
Ile50 del dominio TAD2 di p53 sono fondamentali per l’interazione con tfb1/p62. Tali 
residui occupano una faccia dell'elica anfipatica e stabiliscono delle interazioni 
idrofobiche con TFIIH, mentre il residuo Glu51 stabilisce interazioni elettrostatiche 
fondamentali per la stabilizzazione del complesso. Queste informazioni dimostrano 
che l'interazione tra p53 e tfb1 è basata su un riconoscimento di superficie, in cui è 
necessaria la presenza della struttura elicoidale del frammento 47-55 di p53 per un 
corretto orientamento dei residui coinvolti nel legame.  
 
 
Il dominio POZ/BTB e la famiglia di proteine KCTD 
 
Il dominio POZ/BTB (Drosophila melanogaster bric-à-brac, tramtrack and broad) è 
stato ritrovato in molte proteine con differenti funzioni: repressione della trascrizione, 
regolazione del citoscheletro, canali ionici e proteine coinvolte nel processo di 
ubiquitinazione e degradazione. In tutti i domini POZ/BTB è possibile identificare un 
motivo strutturale comune caratterizzato da tre foglietti beta allineati e cinque alfa 
eliche, coinvolto in numerose interazioni proteina-proteina. 
Questo dominio è altamente conservato nella regione N-terminale di una nuova 
famiglia di proteine KCTD (K+ Channel Tetramerization Domain), i cui membri 
sembrano essere coinvolti in numerosi processi biologici.  
Differenti studi hanno dimostrato che la maggior parte delle proteine KCTD 
interagisce con le culline, una famiglia di 7 proteine conosciute come ubiquitina-
proteina ligasi, che legano molecole di ubiquitina alla proteina bersaglio, che viene 
così riconosciuta dal proteasoma e degradata.  
La comprensione delle basi molecolari del riconoscimento tra il dominio POZ/BTB e 
le culline è importante per la progettazione di nuove molecole utili per applicazioni 
biotecnologiche. 
KCTD11 è un oncosoppresore antagonista della rete di segnali denominati 
Hedgehog (Hh) ed è coinvolto nella deacetilazione e attivazione di Gli1 e Gli2 [12], 
due fattori di trascrizione chiave nella via metabolica di Hh. KCTD11 forma un 
complesso multiproteico con la Cullina3 (Cul3) e HDAC mediando la deacetilazione 
di Gli1 nella rete di segnali di Hh.  
Recentemente il gruppo della dott.ssa Pedone dell’IBB-CNR di Napoli, ha proposto 
un modello di interazione tra KCTD11 e Cul3 derivato dalla struttura cristallografica di 
Skp1/Cul1, omologhi rispettivamente di KCTD11 e Cul3. In questo modello ogni 
subunità del dominio POZ/BTB del tetramero di KCTD11 interagisce con una 
molecola di Cul3. In particolare, l'α-elica della regione 49-68 di Cul3 si posiziona 
all'interfaccia tra le varie subunità del dominio POZ/BTB. Inoltre, è stato proposto che 
i residui Tyr58, Tyr62 e Tyr125 di Cul3 e il residuo Phe102 di KCTD11 sono 
fondamentali per l’interazione (Figura 2). 
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RISULTATI OTTENUTI 
 
Sulla base delle informazioni strutturali a disposizione, un approccio simile è stato 
utilizzato per entrambe i sistemi studiati. Sono stati infatti progettati e sintetizzati 
peptidi che, conservando i residui fondamentali per l'interazione, hanno una buona 
propensione ad assumere una conformazione elicoidale, necessaria per il 
riconoscimento dei bersagli proteici. 
 
Progettazione, Sintesi, Caratterizzazione strutturale e Attività in vitro ed in vivo di 
peptidi analoghi di p53 TAD2 
 
Uno degli obiettivi della presente tesi è stato quello di ottenere un potenziale dominio 
di transattivazione artificiale, partendo dai dati strutturali relativi al complesso tra p53 
TAD2 e tfb1 di TFIIH. 
L'analisi di tale struttura ha evidenziato il ruolo chiave per l'interazione dei residui 
Ile50, Glu51, Trp53 e Phe54 situati nella regione elicoidale 45-57 di p53 TAD2.  
Sono state progettate due generazioni di peptidi, entrambe contenenti la sequenza 
45-57 di p53. 
Nella prima generazione di peptidi mimetici di p53 TAD2 sono stati conservati i 
residui fondamentali per il riconoscimento di TFIIH e sono state aggiunte opportune 
sequenze denominate N- e C-capping. Questi sequenze si ritrovano all'inizio e alla 
fine di strutture elicoidali, dove formano legami a idrogeno e interazioni idrofobiche 
specifiche che aumentano la propensione alla formazione di un' α-elica della 
sequenza proteica. Inoltre, nei peptidi le estremità N- e C-terminali sono state 
rispettivamente acetilate e ammidate per eliminare le cariche presenti che possono 
essere cause di destabilizzazione dell'elica.  
In particolare, il peptide p53-13 contiene la sequenza naturale 45-57 della proteina 
p53 con le due estremità acetilate e ammidate.  
Il peptide NC17 è formato da 17 amminoacidi, conserva i residui fondamentali per il 
riconoscimento di TFIIH e contiene un residuo di Glu al posto della Gln52 in modo da 
formare un ponte salino i, i+4 con la Lys all’estremità C-terminale. I residui dei motivi 
N-capping e di Schellman al C-terminale inseriti nella sequenza sono stati scelti in 
base alla loro frequenza statistica in quelle posizioni.  
Il peptide NC15 contiene 15 residui, lo stesso motivo N-capping di NC17 e in questo 
caso i residui di Trp53 e Phe54 fanno parte del motivo di Schellman per la 
stabilizzazione della conformazione elicoidale. 
Tutti i peptidi sono stati sintetizzati in fase solida utilizzando la chimica Fmoc. I 
prodotti ottenuti sono stati purificati mediante RP-HPLC preparativo. La purezza e 
l’identità dei peptidi sono state verificate mediante LC-MS.  
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Peptidi Sequenze
p53-13      Ac-45Leu-Ser-Pro-Asp-Asp-50Ile-Glu-Gln-Trp-Phe-55Thr-Glu-Asp-NH2 
NC17 Ac-Leu-Thr-Pro-Asp-Glu-Phe-Ile-Glu-Glu-Trp-Phe-Leu-Lys-Asp-His-Gly-Ile-NH2 
NC15     Ac-Leu-Thr-Pro-Asp-Glu-Phe-Ile-Glu-Gln-Trp-Phe-Lys-His-Gly-Ile-NH2 	  
	  
Tabella 1. Sequenze amminoacidiche dei peptidi mimetici di p53 TAD2 della prima generazione. 
In rosso sono evidenziati i residui fondamentali per l'interazione, in blu i residui appartenenti al 
motivo N-capping mentre in verde i residui del motivo di Schellman. 	  
 
Al fine di studiare le proprietà conformazionali dei peptidi sintetizzati sono state 
eseguite misure di dicroismo circolare. Lo spettro CD di p53-13 è caratterizzato da 
un profondo minimo a 200nm, caratteristico dell’assenza di struttura secondaria 
definita.  
Lo spettro CD del peptide NC15 presenta due minimi a 206 e 220 nm, un crossover 
(λ0) a 199nm ed un massimo intenso a 193 nm, indice di un buon contenuto di 
struttura elicoidale. Lo spettro CD del peptide NC17 presenta invece due minimi a 
202 e 221 nm, non presenta crossover, indicando uno scarso contenuto di struttura 
elicoidale. 
Per valutare l'affinità di legame per il dominio PH di tfb1 dei peptidi sintetizzati sono 
stati effettuati esperimenti ITC in collaborazione con il gruppo del professore 
Omichinski dell'Università di Montréal in Canada. I risultati ottenuti hanno mostrato 
che il peptide p53-13 ha una costante di dissociazione apparente (Kd) di 1,6 ±0,3 µM 
per tfb1, mentre NC15 e NC17 non sono stati in grado di legare tfb1.  
Questi dati sono stati confermati anche da esperimenti di etero-correlazione 1H-15N 
NMR. La titolazione di tfb1 con il peptide p53-13 ha evidenziato che quest’ultimo 
compete con lo stesso sito di legame di p53 TAD2.  
Studi analoghi condotti sui peptidi NC15 e NC17 non hanno evidenziato significativi 
spostamenti dei segnali di tfb1.  
La seconda generazione di peptidi è stata progettata sulla base dei dati riportati in 
letteratura sul peptide mimetico del fattore VEGF (QK). In queste sequenze sono 
stati inseriti un motivo N-capping e due residui di Leu in posizione i, i+3. 
I peptidi differiscono tra loro per alcune modifiche apportate all’interno del motivo N-
capping. In particolare, nella sequenza di E-Cap il Glu in posizione 3 è stato scelto in 
base a dati statistici relativi alla probabilità di trovare il residuo in tale posizione; in W-
Cap il Trp in posizione 3 è stato scelto per omologia con il peptide QK; mentre in A-
Cap l’Ala in posizione 3 è stato scelta per analogia con VP16C, un fattore di 
trascrizione, capace anch’esso di legarsi a tfb1. 
I residui di leucina sono stati inseriti nelle posizioni 6 e 9, rispettivamente in i e i+3 
dell’elica, in quanto questi residui contribuiscono alla stabilizzazione della 
conformazione elicoidale attraverso interazioni idrofobiche e si trovano sul lato 
dell’elica opposto a quello dell’interazione con tfb1.  
I peptidi sono stati sintetizzati in fase solida utilizzando la chimica Fmoc ed i prodotti 
ottenuti sono stati purificati mediante RP-HPLC preparativo. La purezza e l’identità 
dei peptidi sono state verificate mediante LC-MS. 
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Peptidi Sequenze
E-Cap Ac-Leu-Thr-Glu-Glu-Glu-Leu-Ile-Glu-Leu-Trp-Phe-Thr-Glu-NH2 
A-Cap Ac-Leu-Thr-Ala-Glu-Glu-Leu-Ile-Glu-Leu-Trp-Phe-Thr-Glu-NH2  
W-Cap Ac-Leu-Thr-Trp-Glu-Glu-Leu-Ile-Glu-Leu-Trp-Phe-Thr-Glu-NH2 	  
	  
Tabella 2. Sequenze amminoacidiche dei peptidi mimetici di p53 TAD2 della seconda 
generazione. 
In rosso sono evidenziati i residui fondamentali per l'interazione, in verde i due residui di Leu 
in posizione i, i+3, in blu le modifiche apportate al motivo N-capping 
 
Le sequenze ottenute sono state analizzate mediante tecniche di dicroismo circolare 
per valutarne il contenuto elicoidale. Gli spettri CD presentano due minimi a 222nm e 
207nm, un crossover tra 193 e 197 nm e un massimo a ~190nm, indice di un 
contenuto elicoidale simile, maggiore rispetto al peptide p53-13 ma inferiore a quella 
di NC15. 
Analisi di interazione mediante ITC hanno mostrato che E-Cap, W-Cap e A-Cap sono 
in grado di legarsi a tfb1, con una Kd rispettivamente di 0.24 ± 0.03 µM, 1.3 ± 0.1 µM 
e 1.9 ± 0.3 µM.  
Esperimenti di etero-correlazione HSQC 1H-15N NMR hanno evidenziato che tutti i 
peptidi della nuova generazione provocano un cambio dei segnali di tfb1 nella 
regione localizzata tra i foglietti β5, β6 e β7 e il loop tra β5 e β6. Inoltre sono stati 
condotti degli studi su E-Cap per comprendere come la presenza delle due leucine 
influisce sulla capacità di legame.  
La struttura di E-Cap in complesso con tfb1 conferma che i residui Leu6 e Leu9 
formano un ponte idrofobico, sul lato opposto dell'elica rispetto a quello 
dell'interazione. Inoltre, la Leu6 stabilizza ulteriormente la struttura elicoidale di E-
Cap formando dei contatti con l'anello aromatico del Trp10 in posizione i+4. 
La potenziale funzione di E-Cap come attivatore della trascrizione in vivo è stata 
analizzata esprimendo in cellule di lievito E-Cap legato a LexA, un dominio di legame 
al DNA specifico per il gene reporter lacZ. Oltre al controllo positivo Gal4, la capacità 
di attivatore della trascrizione di E-Cap è stata paragonata a quella di altri attivatori 
AH e VP2 e alla sequenza p53-13 anch'essi co-espressi con LexA.  
E-Cap ha mostrato una capacità di attivazione della trascrizione maggiore rispetto 
alle altre sequenze, confermando che stabilizzando la conformazione elicoidale di 
piccoli analoghi di p53 è possibile creare dei potenti domini di transattivazione 
artificiali.  
Tali peptidi saranno ulteriormente ottimizzati per lo sviluppo di attivatori artificiali di 
trascrizione con elevate potenzialità applicative nel campo delle biotecnologie. 
 
 
Progettazione, Sintesi, Caratterizzazione strutturale e Saggi ELISA di peptidi 
analoghi di Cul3 
 
Lo sviluppo di mimetici di Cul3 specifici per l'interazione con il dominio POZ/BTB 
della regione N-terminale di KCTD11 sono stati condotti in collaborazione con il 
gruppo della dr.ssa Pedone e della dr.ssa Di Gaetano presso l’IBB-CNR di Napoli. 
Precedenti studi di mutagenesi e modellistica molecolare hanno evidenziato che la 
regione che media il riconoscimento tra Cul3 e KCTD11 presenta dei residui 
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aromatici fondamentali per l’interazione (Tyr58, Tyr62 e Tyr125 di Cul3 e Phe102 e 
Tyr102 di KCTD11) [13].  
Sulla base di questi studi un altro obiettivo del presente lavoro di ricerca è stato 
quello di progettare analoghi di Cul3 in grado di legare il dominio POZ/BTB di 
KCTD11, allo scopo di contribuire alla comprensione dei determinanti strutturali 
fondamentali per l'interazione tra Cul3 e la famiglia di proteine KCTD. 
Inizialmente, è stato progettato il peptide Cul3-wt corrispondente alla regione 49-68 
di Cul3. Successivamente sono stati progettati due analoghi, Cul3-KK e Cul3-Y(P), in 
cui la Tyr58 e la Tyr62 sono state sostituite rispettivamente con due residui di Lys e 
un residuo di Tyr fosforilata, in modo da verificare l’importanza nell’interazione di 
questi residui. 
 
Peptidi Sequenze
Cul3-wt Ac-49Asn-Ser-Gly-Leu-Ser-Phe-55Glu-Glu-Leu-Tyr-Arg-60Asn-Ala-Tyr-Thr-Met-65Val-Leu-His-Lys-NH2!
Cul3-KK Ac-Asn-Ser-Gly-Leu-Ser-Phe-Glu-Glu-Leu-Lys-Arg-Asn-Ala-Lys-Thr-Met-Val-Leu-His-Lys-NH2!
Cul3-Y(P) Ac-Asn-Ser-Gly-Leu-Ser-Phe-Glu-Glu-Leu-Tyr(P)-Arg-Asn-Ala-Tyr-Thr-Met-Val-Leu-His-Lys-NH2! 	  
	  
Tabella 3. Sequenze amminoacidiche dei peptidi Cul3-wt, Cul3-KK e Cul3-Y(P). 
In rosso sono evidenziate le Tyr fondamentali per l'interazione, in verde le Lys che 
sostituiscono le Tyr e in blu la Tyr fosforilata. 
 
Tutti i peptidi sono stati acetilati al N-terminale e ammidati al C-terminale  in modo da 
eliminare le cariche presenti che possono destabilizzare il dipolo dell’elica. Inoltre 
sono stati sintetizzati anche i derivati biotinilati da utilizzare per gli studi di interazione 
in vitro, mediante saggi ELISA. 
I peptidi sono stati sintetizzati in fase solida utilizzando la chimica Fmoc. I prodotti 
ottenuti sono stati purificati mediante RP-HPLC preparativo. La purezza e l’identità 
dei composti sono state verificate mediante LC-MS. 
L’analisi conformazionale mediante dicroismo circolare ha evidenziato un basso 
contenuto di struttura elicoidale sia per Cul3-wt che per Cul3-KK. Gli spettri CD di 
entrambi i peptidi mostrano, infatti, un minimo intorno a 222nm e un profondo minimo 
a 202-203 nm, un cross-over a 192nm e un massimo a 190nm. 
Studi preliminari di interazione con KCTD11 sono effettuati mediante saggi ELISA 
per confermare la capacità di Cul3wt di interagire e valutare se Cul3-KK e Cul3-Y(P), 
si legano con minore affinità. L’andamento delle curve risultanti dagli esperimenti 
indica che Cul3-wt si lega al dominio POZ/BTB di KCTD11 con una discreta affinità, 
mentre i due mutanti si legano con un'affinità inferiore. 
Come nel caso degli analoghi di p53 TDA2, è stato progettato un peptide che 
presenta un maggiore contenuto elicoidale per valutare l’effetto sull’affinità per 
KCTD11. In particolare alla sequenza nativa di Cul3 sono stati sostituiti i residui 
Leu57 e Ala61 con due α,α-amminoacidi, α-(4') pentenil- alanina (S5). Questi residui 
permettono di creare un ponte idrocarburico mediante reazione di metatesi (RCM) tra 
i residui i, i+4 della sequenza, stabilizzando il peptide in conformazione elicoidale.  
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Peptidi Sequenze
Cul3-stapline Ac-Asn-Ser-Gly-Leu-Ser-Phe-Glu-Glu-S5-Tyr-Arg-Asn-S5-Tyr-Thr-Met-Val-Leu-His-Lys-NH2!
Cul3-stapled Ac-Asn-Ser-Gly-Leu-Ser-Phe-Glu-Glu-S5-Tyr-Arg-Asn-S5-Tyr-Thr-Met-Val-Leu-His-Lys-NH2!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
 
Tabella 4. Sequenze amminoacidiche dei peptidi Cul3-stapline e Cul3-stapled. 
In rosso sono evidenziati i residui necessari per RCM 
 
I peptidi sono stati acetilati al N-terminale e ammidati al C-terminale in modo da 
eliminare le cariche presenti su di esse che possono essere la causa di 
destabilizzazione dell'elica. Anche in questo caso dei peptidi sono stati sintetizzati 
anche i derivati biotinilati da utilizzare per gli studi di interazione in vitro, mediante 
saggi ELISA. 
I peptidi sono stati sintetizzati in fase solida utilizzando la chimica Fmoc. Anche la 
reazione di metatesi è stata condotta in fase solida e i prodotti ottenuti sono stati 
purificati mediante RP-HPLC preparativo. La purezza e l’identità dei composti sono 
stati verificati mediante LC-MS. 
Lo studio conformazionale mediante CD ha evidenziato che Cul3-stapled ed il suo 
analogo lineare Cul3-stapline hanno un buon contenuto elicoidale, simile tra loro e 
sicuramente maggiore rispetto a Cul3-wt. 
L’analisi preliminare dei risultati ottenuti dai saggi ELISA ha confermato che entrambi 
i peptidi sono in grado di legarsi al dominio POZ/BTB di KCTD11 con un'affinità 
maggiore rispetto a Cul3-wt. 
Studi futuri mediante tecniche ITC ed NMR saranno effettuati per determinare la 
costante di affinità e per comprendere le basi molecolari dell'interazione con il 
dominio POZ/BTB di KCTD11 e di altri membri della famiglia di proteine KCTD. 
Recenti dati di letteratura indicano infatti che molti domini POZ/BTB di questa classe 
di proteine mediano l' interazione con Cul3. Pertanto, lo sviluppo di molecole in grado 
di legare questi sistemi proteici coinvolti in numerose patologie umane può essere un 
punto di partenza per lo sviluppo di interessanti agenti terapeutici. 
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1. INTRODUCTION 
 
 
Sequencing of the human genome has greatly expanded the knowledge of the 
primary structures of proteins.  
Proteins play a central role in key biological signaling processes and these events 
require protein interaction networks.  
The study of the protein-protein interactions (PPI) is fundamental to correlate 
structure and function in biomolecular systems. The understanding of molecular 
features that regulate these interactions is the starting point for the design of specific 
ligands able to modulate main cellular activities allowing the development of new 
systems for biotechnology applications. 
 
 
1.1 Protein-Protein interactions: Structural Basis 
 
In PPI independently folded domains of proteins form an interface in which residues 
located on different protein chains take place, giving arise to interaction surfaces 
(Figure 1) [1]. 
 
	  
Figure 1. The figure represents two interacting proteins (human glutathione S-transferase, PDB 
ID: 10GS). [Keskin, O.,et al., J Mol Biol, 2005] 
 
 
Some proteins exert their functions just in complexed form, so that PPI in this case 
can be defined as "obligate" or "permanent" [2]. Generally these kinds of protein 
complexes represent important cellular machinery such as proteasome, ribosome, 
DNA replication and transcription, ATP synthase and many others [3]. The 
interactions between different subunits of these complexes are very strong showing 
binding affinity (Kd) values in nM range [2]. 
Many others proteins interact "transiently" since the interaction is broken and formed 
continuously and the complex readily undergoes changes in the oligomeric state. In 
	   14	  
this case the binding affinity between different proteins is weak with Kd values 
typically in µM range.  
Thornton and co-workers [4] [5] have highlighted that it is possible to identify different 
protein transient associations: weak transient complexes that show a dynamic 
mixture of different oligomeric states and strong transient complexes where proteins 
interact only after an activation signal. However, a continuum between transient and 
obligate interaction occurs and the stability of all complexes depends on the 
physiological conditions and cellular environment. 
 
 
 
 	  
Figure 2. Different Types of Protein-Protein Interactions on the Basis of Their Binding Affinities 
[Perkins, J.R., et al., Structure, 2010] 
 
 
 
The analysis of interacting interfaces that determine the stability of the complex such 
as size, shape and surface complementarity is required for the knowledge of 
molecular properties that regulate PPI [4], [5]. 
Ramos and co-workers [6] have described that the standard-size of PPI interfaces is 
1200–2000 Å2, but we can be distinguish different size if binding affinity is more or 
less strong. Large size interfaces in the range 2000–4660 Å2 occur mostly between 
proteases and a particular class of inhibitors, G-proteins and other components of the 
signal transduction system [6].  
Inside the surface area different kinds of forces contribute to the binding free energy 
of PPI.  
Hydrophobicity is a leading force in PPI and hydrophobic interactions in proteins 
occur between amino acid residues of nonpolar regions through van der Waals 
contacts [5] [6]. 
Electrostatic force is a further force involved in PPI and electrostatic complementarity 
of interacting protein surfaces promotes complex formation and defines the lifetime of 
complexes [6]. 
Hydrogen bonds are formed between protein contact surfaces and the surrounding 
water molecules [5] and their average number is proportional to the area of subunit 
surfaces.  
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Summing the free energy gain produced by all the individual van der Waals, 
electrostatics interactions and by desolvation process, the total gain produces a high 
stabilization of the protein–protein complex. 
It is observed that there is a higher conservation of residues in interfaces than in the 
rest of protein and some of these contribute dominantly to the binding free energy.  
The average percentage of aromatic residues in interfaces demonstrates their 
importance in PPI. 
Tryptophan is a hydrogen-bonding donor and contributes with its indole ring to 
aromatic π-interactions. Moreover, it has a large hydrophobic surface and can protect 
fragile hydrogen bonds from water. Its mutation to an alanine generates a large 
cavity, due to the significant difference in sizes, which can create a highly complex 
destabilization. 
Tyrosine has both the phenolic ring that can participate to aromatic π-interactions 
and the 4-hydroxyl group that make hydrogen bonds.  
Other amino acids are most frequently found in interfaces of PPI. Arginine is capable 
of multiple types of favorable interactions by its guanidinium group such as hydrogen 
bond and salt-bridge. Analysis of various complexes shows that aspartate and 
asparagine are favored over glutamate and glutamine and isoleucine is more 
frequent than leucine [6]. 
Systematic substitutions of these residues in the interfaces by alanine (Ala scanning) 
and the measurement of the difference in binding free energy between the wild type 
protein and the mutants, have highlighted a substantial decrease. The sites where 
alanine mutations cause a significant drop in the binding free energy of at least 2.0 
kcal/mol are defined as "hot spots" [7].  
Generally all residues can contribute indirectly to PPI favoring the orientation of "hot 
spots" and/or contributing by electrostatic contacts [6].  
"Hot spots" tend to organize packing tightly and to form networks of interactions that 
are called “hot regions” [9]. The hot regions of protein-protein interfaces are often 
organized as preferred secondary structures: helices, β-sheets and loops. 
 
 
1.2 Helical structure in Protein Interface 
 
The helical structures represent one of most frequent secondary motifs found in 
proteins and play crucial roles in many PPI [10].  
Most helices located within the protein core are vital for the overall stability of protein 
tertiary structure and some helices exposed on the surface of a protein are bioactive 
regions for the recognition of proteins, DNA and RNA [11]. Recent studies by Arora 
and co-workers highlighted that roughly 60% of the protein complexes found in the 
Protein Data Bank (PDB) display helical interface [12]. 
The α-helix is characterized by a circular rotation of 3.6 residues per complete turn 
that places side-chains in i, i+3, i, i+4 and i, i+7 positions close in the space [10]. The 
carbonyl groups and amide protons in these positions, orientated in opposite 
directions, create hydrogen bonds that run in the same direction along the surface of 
the helix, thus stabilizing the structure. The residues spaced i, i+2, i, i+5 and i, i+6 
place the side-chain pairs on opposite faces of the helix, avoiding any interaction in a 
monomeric helix.  
Other kinds of helical structures are occasionally found in proteins and in naturally 
occurring peptides such as 310- and π-helices. 
The 310-helix occurs in about 3-4% of residues in protein crystal structures, usually at 
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the N- and C-terminal of α-helices. It is characterized by more tightly wound than the 
α-helix with hydrogen bonds between i, i+3 residues. The resulting steric clash 
renders this conformation less favorable than the α-helix. There is no energy barrier 
between 310-helical and α-helical structures, and the two forms can therefore easily 
interconvert, so that the 310-helix is proposed to be an intermediate in the α-helices 
formation [10].  
The π-helix is extremely rare and energetically unfavorable respect with α-helix. Its 
geometrical features enforce hydrogen bonds between i, i+5 residues. Evidence for 
π-helices show that are more likely to be associated with protein function than 
structure of proteins [10], [11]. 
Several examples of helical surface that plays a major role in mediating a PPI are 
reported in the literature.  
The interaction between trans activation domain (TAD) of p53 and Mdm2 is one of 
most studied case of PPI involving an α-helix (Figure 3A) [3]. The anti-apoptotic 
proteins Bcl-xL and Mcl-1 that exert their effect sequestering pro-apoptotic proteins 
(such as BAK) through the interaction with key residues exposed from an α-helix 
surface [3] (Figure 3B) and the hypoxia inducible transcription factor (HIF-1) that 
interacts through its three distinct α-helical motifs with coactivator CBP (Figure 3C), 
represent other examples [3]. 
 
 
 
 
p53 TAD1  
Mdm 
BAK 
Bcl-xL 
CBP 
HIF-1 
A B C
 
 
Figure 3. A. In p53/Mdm2 interaction three residues from a helix  (in red) in the p53 activation 
domain reside in a Mdm2 deep hydrophobic groove (PDB code: 1YCR) B. The interaction 
between Bcl-xL and BAK involves four key hydrophobic residues of BAK (purple) binding 
within a hydrophobic cleft on Bcl-xL (PDB code: 1BXL) C. HIF-1 (green) binds to CBP (cyan) 
through three distinct α-helical motifs (PDB code: 1L8C). 
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1.3 Helical structure mimetics: Peptides and Peptidomimetics 
 
The inhibition of molecular interactions as PPI is a promising strategy for the 
controlled interference of biological functions. This approach requires the availability 
of molecules or library of molecules capable of conformationally mimicking defined 
surface of binding preserving the right arrangement of functional sites.  
It is possible to recognize two structural types of protein binding sites: sequentially 
continuous binding sites that are located in single, defined stretches of the protein 
sequence and discontinuous binding sites where the amino acids are not located in 
continuous stretches of the sequence but are placed into spatial proximity by protein 
folding [13].  
As previously reported, α-helices constitute the largest class of protein secondary 
structures and play a considerable role in mediating protein–protein interactions. 
Recent analysis by Arora and co-workers of the PDB highlight that 62% of the 
resolved protein complexes are featured by helical interfaces and that the average 
length of helical domains in interacting interfaces is rather small and spans two to 
three helical turns (or eight to twelve residues) [14]. These complexes suggest that it 
may be possible to develop small molecules that potentially interfere with the 
interactions between biomolecules. Peptides are adequate molecules to mimic 
protein-binding site, enabling the detailed analysis of the interaction at the level of 
individual amino acid residues [15]. They are able to reproduce protein secondary 
structures of selected interface with high affinity and specificity. Moreover, since 
recent progresses in chemical synthesis methods it is possible to introduce different 
building blocks and modification at peptide backbone. Unfortunately, peptides 
composed of less than fifteen amino acid residues rarely retain their conformation 
once excised from the protein and the ability to bind their specific targets [16, 17]. 
Stabilization of peptides in the helical structure should reduce their conformational 
heterogeneity and increase their resistance to proteases as these enzymes typically 
bind their substrates in the extended conformation. The proteolytic stability of the 
helix should thus be directly proportional to its conformational stability [17].  
The scientific community focuses much of its attention on studying different 
approaches to either stabilize the α-helical conformation in peptides and mimic this 
motif with natural and non-natural scaffolds. These approaches can be summarized 
into three general categories: helix stabilization, helical foldamers and helical surface 
mimetics.  
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Figure 4. Strategies that stabilize the α-helical conformation in peptides or mimic this domain 
with non-natural scaffolds [Patgiri, A., et al., Acc. Chem. Res., 2008] 
 
 
Since the discovery of α-helix structure in proteins, several studies have provided a 
set of rules for helix stabilization introducing several molecular tools such as amino 
acids residues with large helix forming propensities, aliphatic and aromatic residues 
that allow hydrophobic van der Waals interaction, polar and charged amino acids that 
promote stabilizing hydrogen bonds, amino acid residues able to stabilize aromatic-
charge or aromatic-sulfur interactions, N- and C-capping groups that prevent 
unfavorable charge interactions with the helix dipole  [18]. 
The spatial proximity of residues placed at positions i, i+4 in an α-helix is further 
exploited to stabilize helices by the incorporation of metal ligands at these positions 
introducing natural or diacetic-based unnatural amino acids [18]. 
Along with the helix-coil transition theory in peptides, another approach for helix-
stabilization consists of introducing constraints or non natural amino acids to form 
covalent bonds between the i, i+4 and i, i+7 side chain groups. Lactam [19] and 
disulfide bridges [20] have been the earliest side chain crosslinks used. 
Recently, further covalent helix stabilization is achieved by Grubbs and co-workers 
using ruthenium-catalyzed ring-closing metathesis (RCM) of O-allyl serine residues 
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to introduce olefinic crosslinks between i, i+4 and i, i+7 positions in a helical 
sequence [21]. Likewise, Schafmeister and Verdine have described hydrocarbon 
bridged helices obtained by olefin metathesis reaction [22]. The hydrocarbon linker is 
employed because it is expected to be chemically more stable than linkers built from 
amide or disulfide bonds. These hydrocarbon-stapled peptides also show an 
increased tendency to penetrate the cell membrane likely for the lipophilic nature of 
the linker [23].  
In the last years click chemistry is emerged as a good synthetic tool to insert 1,4-
disubstituted triazole linkage as isostere of the amide bond in peptide structure [24]. 
Recently, Dawson and co workers have described an efficient method for side-chain 
cyclization of peptides by click chemistry, introducing cross-link between i, i+3 side-
chain groups and favoring the formation of an α-helix structure [25]. 
Helical foldamers, such as β-peptides and peptoids (Figure 4), are composed of 
amino acid analogues and are capable of adopting conformations similar to those 
found in natural proteins [17]. Foldamer design, based on heterogeneous backbones, 
is more advantageous relative to homogenous backbones (Figure 5) [26]. The 
number of candidate backbones is indeed larger if heterogeneous backbones for a 
given set of monomer classes are included. For example if only α- and β-amino 
acids as building blocks are considered, the homogeneous approach limits the use to 
α-peptides or β-peptides while the heterogeneous approach allows many different 
combinations (such as α-β-α-β-α-β-, α-α-β-α-α-β-, α-β-β-α-β-β-, α-α-β-β-, to 
name just a few). Each of these heterogeneous backbones offers a potentially 
distinctive way to project sets of side chains in the space. By analogy to proteins, a 
specific three-dimensional arrangement of these side-chains allows more distinct 
shapes that can be generated with foldamers.  
 
α-Peptide β-Peptide α,α,β-Peptide α,β,β-Peptide  	  
Figure 5. Helical Foldamers: The heterogeneous approach [Horne, W.S. and S.H. Gellman, 
Acc. Chem. Res., 2008] 
 
 
Many helix structures consisting of β-peptides are also reported. These conformation 
types are distinguished by the number of atoms in the hydrogen-bonded ring that is 
formed in solution: 8-helix, 10-helix, 12-helix, 14-helix, and 10/12-helix. Generally β-
peptides form a more stable helix than α-peptides [27].  
Finally, the helical surface mimetics utilize conformationally restricted scaffolds with 
attached functional groups that resemble the i, i+4 and i, i+7 pattern of side chain 
positioning along the face of an α-helix [12]. These mimetics generally derive from 
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small building blocks. For example Hamilton and coworkers have introduced 3,2',2'-
functionalized terphenyl derivatives as structural and functional mimetics of α-helices 
[28] acting as potent antagonists of calmodulin and inhibitors of the assembly of the 
hexameric HIV fusion protein gp41 [29]. More recently they have designed a new α-
helix scaffold that mimic the α-helical BH3 domain of Bak. This moiety consists of a 
trispyridylamide scaffold that exhibits a preferred conformation with all O-substituents 
located on the same side of the molecule mimicking the i, i+4 and i, i+7 residues in 
the α-helix. 
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1.4 p53 Protein 
 
1.4.1 p53: a cancer suppressor 
 
The p53 gene was the first tumor-suppressor gene to have been identified. It 
expresses for a nuclear protein of 393 amino acids, a key regulator protein for cell 
cycle regulation, apoptosis and DNA repair [30]. 
Normally, p53 protein cellular levels are very low because it has a short half-life. Its 
localization and degradation are mediated by Mdm2 that binds p53 protein blocking 
its transcriptional action and tagging for ubiquitin-dependent proteolysis degradation. 
Mdm2 is also the main transcriptional target for p53 protein, directly activating 
expression of its own negative regulator and producing a potent negative feedback 
regulatory loop. It is worth to note that the regulation of p53 occurs post-
translationally, since such kind of regulation would appear to be optimal in a stress 
response. p53 protein levels have been shown to dramatically rise in response to 
different stresses, including ionizing and UV radiations, growth factor deprivation, 
treatment with chemotherapeutic drugs, oncogene activation, heat shock or virus 
infections. p53 protein expression has also been shown to be induced following 
hypoxia in the early stages of tumorigenesis, explaining what p53 loss may be 
selected for. The primary phenotypic consequences of p53 induction are cell cycle 
arrest or apoptotic cell death. Alterations in p53 protein expression or in its regulated 
signals cascade are the main causes of ~50% human tumors, therefore this protein 
and its network have been subject of many studies to design and synthesize ligands 
that can modulate its functions [31].  
Active form of p53 protein is a phosphorylated tetramer polypeptide that works as a 
potent transcriptional activator [32], [33]. 
In the structure of protein it is possible to recognize 5 different functional domains 
(Figure 6): 
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Figure 6. Domain organization of p53: The amino-terminal transactivation domain (TAD) is 
natively unfolded and interacts with components of the transcriptional machinery and includes 
the Mdm2 and TFIIH binding site. The central DNA binding “core” domain (DBD) holds 95.1 % 
of the oncogenetic mutations. The carboxy-terminal region of p53 consists of a tetramerization 
domain (TET) and a regulatory domain (RD). [Romer L., et al, Angew Chem Int Ed, 2006] 
 
(i) the transactivation acidic domain (TAD) at N-terminal region that encodes the 
transactivation function. This region is relatively acid and has been shown to interact 
with components of the transcriptional machinery, such as TATA-binding protein 
(TBP), TBP-associated factors (TAFs) and the co-activator proteins p300/CBP. The 
Mdm2 oncoprotein has been shown also to bind p53 in the N-terminal region where it 
negatively regulates p53 transactivation function; 
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(ii) a proline-rich domain located adjacent to the TAD domain that is functionally 
important for p53 tumor suppressor activity;  
(iii) a central DNA binding domain (DBD). The main p53 mutations are found within 
this region and disrupt DNA binding by p53;  
(iv-v) the C-terminal region of p53 has a relatively basic charge and contains 
sequence-nonspecific DNA binding activity. A discrete region within this C-terminal 
domain regulates oligomerization of p53. The C-terminal domain also contains 
several nuclear localization signals as well as a nuclear export signal that is thought 
to regulate p53 subcellular localization.  
 
 
1.4.2 p53-TFIIH interaction 
 
The N-terminal region TAD of p53 protein has been extensively studied because it is 
associated to the transcriptional activation function of the protein [34]. This region is 
rich of acidic residues and can be divided in two subdomains, TAD1 (residues 1-40), 
and TAD2 (residues 40-83) that show independent transcriptional activation functions 
[35]. 
TAD1 and TAD2 functionally interact with a variety of transcriptional regulatory 
proteins. TAD1 specifically recognizes Mdm2, the TBP and CBP/p300, whereas 
TAD2 interacts with the replication protein A (RPA70) and others.  
The transcription factor II H (TFIIH) is one of general transcription factors (GTF) 
known to be a target of TAD2 of p53. TFIIH is composed of ten subunits that can be 
divided into two groups, the core (XPB [Ssl2], p62 [Tfb1], p52 [Tfb2], p44 [Ssl1], p34 
[Tfb4], and TTDA [Tfb5] in human and yeast respectively) and the CAK complex 
(cdk7 [Kin28], cyclin H [Ccl1], and MAT1 [Tfb3]) that are linked by XPD [Rad3] 
subunit. TFIIH is the only GTF to possess enzymatic activity and its helicase 
activities (XPB and XPD) are essential to the formation of the open complex during 
transcription initiation, whereas its kinase activity (cdk7) is required for the 
phosphorylation of the C-terminal domain of the RNA Pol II largest subunit. This 
phosphorylation enables RNA Pol II to progress from the initiation phase to the 
elongation phase of transcription [36].  
The interaction between p62 subunit of TFIIH core (tfb1 in yeast) and TAD of p53 
protein has been shown to be important for the recruitment of p53 to the TFIIH 
complex [35]. This interaction is directly correlated with the ability of the p53 TAD to 
stimulate transcriptional elongation. In addition, TFIIH plays a role in regulating the 
transcriptional activity of p53. The phosphorylation of the TAD of p53 at Ser33 by the 
cdk7 is required for p53 to induce apoptosis in response to UV and ionizing radiation 
damage. 
In the recent years Omichinski and co-workers have been interested in the study of 
interaction of TAD of different transcription factors with p62/tfb1 subunit of TFIIH [35], 
[37], [38].  
The structure of interaction between p5320-73 TAD2 with tfb1 subunit of the general 
transcription factor TFIIH has been solved by NMR. Tfb1 subunit of TFIIH has been 
chosen because of longer stability respect with p62; moreover the authors have 
demonstrated that tfb1 and p62 interact with TAD2 in similar way. 
The structure of Tfb1 in the complex presents a typical PH fold (Figure 7), which 
consists of two perpendicular antiparallel β-sheets arranged in a β-sandwich and 
flanked on one side by a long α-helix.  
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Figure 7. Ribbon model for the lowest-energy conformer of the complex Tfb1 (in green)/p53 (in 
red) (PDB code: 2GS0). [Di Lello, P., et al. Mol Cell, 2006] 
 
 
The p53 TAD2 in the complex is unstructured except for a short amphipathic α-helix 
involving residues 47–55. This short helix interacts with the surface of Tfb1 formed by 
β-strands β5, β6, and β7 and the loop connecting β5 to β6 (Figure 7). The surface of 
this region is characterized by the presence of some positively charged residues, 
Lys47, Arg61 and Arg86 that help to position the negatively charged residues of p53 
TAD2. 
The hydrophobic side of TAD2 helix interacts with tfb1 by three fundamental 
hydrophobic residues (Phe54, Trp53 and Ile50) establishing a series of close 
contacts (Figure 8). The aromatic side chain of Phe54 fills a shallow pocket formed 
by Gln49, Ala50, Thr51, Met59, Leu60, and Arg61 of tfb1. In this location, the 
aromatic ring of Phe54 is positioned to participate in an amino-aromatic interaction 
with Gln49 and in a cation-π interaction with Arg61 of tfb1. The indole ring of Trp53 is 
inserted into a narrow cleft formed by the side chains of Met59 and Lys57 of tfb1. In 
this orientation, the side chain of Trp53 is positioned to make a cation-π interaction 
with Lys57 on one side of the indole ring and a sulfur-π interaction with Met59 on the 
other side. The third hydrophobic residue of p53, Ile50 makes van der Waals 
contacts to Met 59 and Met88 of tfb1.  
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Figure 8. (A) The 3D structure of Tfb1 is shown as a ribbon within the transparent molecular 
surface (in green), whereas the backbone trace of p53 is represented as a tube (in orange).  
(B) The side chains of the three hydrophobic residues (Phe54, Trp53, and Ile50) on the 
amphipathic side of the p53 helix are also shown. The aromatic ring of Phe54 from p53 is 
positioned in a shallow pocket on the surface of Tfb1. [Di Lello, P., et al. Mol Cell, 2006] 
 
 
 
Other acidic residues of p53 TAD2 helix are positioned to mediate complex formation 
with tfb1: Glu56 residue forms a salt bridge with Lys57 of tfb1, contributing to 
stabilize the complex. These four residues are conserved in p53 helix mediating the 
interaction also between p53 TAD2 and tfb1 subunit of TFIIH.  
Further electrostatic interactions involve Glu51 residue of p53 TAD2 and Arg61 or 
Arg86 residues of tfb1. Moreover, two important phosphorylation sites are located on 
TAD2, Ser46 that is phosphorylated by p38 mitogen activated protein kinase (MAPK) 
and Thr55 that is phosphorylated by TATA-associated factor 1 (TAF1). The 
phosphorylation of these two sites has a significant effect on formation of tfb1-TAD2 
complex. Phosphorylation at Ser46 by MAPK and HIPK has been postulated to play 
an important role in p53-induced apoptosis favoring the folding of amphipathic helix 
in 47-55 region, whereas the phosphorylation at Thr55 by TAF1 has been associated 
with an increase in Mdm2-mediated degradation of p53 favoring the folding of TAD1 
helix region that interacts with Mdm2. 
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1.5 KCTD Protein 
 
1.5.1 POZ/BTB Domain 
 
The BTB domain (also known as the POZ domain) was originally identified as a 
conserved motif present in the Drosophila melanogaster bric-à-brac, tramtrack and 
broad (BTB) complex transcription regulators and in many poxvirus zinc finger (POZ) 
proteins [39].  
BTB/POZ domain is typically found in a single copy per protein, but in some proteins 
it is combined with a variety of additional protein-protein interaction domains [40].  
POZ (T1) domains are contained at the N-terminus of all the mammal potassium 
channels and are combined with numerous other domains forming a variety of 
distinct domain architectures. Given the extremely wide representation and functional 
significance of BTB/POZ domains, the structural basis of these interactions is of the 
high interest.  
The biological properties of BTB/POZ-containing proteins seem to be contingent on 
the protein-protein interaction properties of this domain. In particular, BTB/POZ 
domains appear to participate in a variety of processes ranging from transcriptional 
repression/activation [41] to cytoskeletal organization [42]. In several proteins, 
BTB/POZ domains mediate homodimerization or multimerization [43]. 
Several BTB/POZ structures were determined by X-ray crystallography, establishing 
the structural similarity between different examples of the fold [44], [45]. A 
comparison of the solved structures from the PDB of BTB domains such as BTB-ZF 
proteins, Skp1, ElonginC and T1 domains (Figure 9), shows a common region of 
approximately 95 amino acids consisting of a cluster of 5 α-helices constituted in part 
of two α-helical hairpins (A1/A2 and A4/A5), and capped at one end by a short 
solvent-exposed three stranded β-sheet (B1/B2/B3). An additional hairpin-like motif 
consisting of A3 and an extended region links the B1/B2/A1/A2/B3 and A4/A5 
segments of the fold. 
 	  
	  
Figure 9. (A) Superposition of the BTB core fold from currently known BTB structures and (B) 
ribbon model of POZ/BTB domain. The BTB core fold (approximately 95 residues) is retained 
across four sequence families: BTB-ZF, Skp1, ElonginC and T1 families (PDB code: 1BUO, 
1FQV, 1VCB, 1T1D). [Stogios PJ, et al., Genome Biology, 2005] 
 
 
!
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1.5.2 Potassium Channel Tetramerization Domain (KCTD) Proteins 
 
Recently, it was highlighted the presence of POZ/BTB domain in a new class of 
human proteins that share a significant sequence identity (~30%) with the 
tetramerization domain of K+ voltage-gated channel T1 proteins, denoted as KCTD 
(K+ Channel Tetramerization Domain). 
The human genome has 21 kctd genes that encode potassium channel 
tetramerization domain containing proteins. KCTD proteins are soluble with N-
terminal BTB/POZ domains and variable C-terminus [46].  
Although scarce, the information available about KCTD proteins suggest that these 
proteins might be involved in development and cellular differentiation. High 
expression of transcripts in fetal tissues and low levels in adults suggest that they 
play a role during development. Thus, KCTD12 is implicated in the maturation of 
inner ear neurons by linkage to a progressive dominant auditory neuropathy. A point 
mutation in KCTD7 is associated with neurodegeneration and progressive myoclonic 
epilepsy [47]. KCTD5 is reported to interact with human Golgi reassembly stacking 
protein 55 (GRASP55) the first known Golgi target for mitotic ERK signaling [48] and 
phosphorylation for G2 phase Golgi fragmentation [49]. KCTD11 is proposed to 
suppress Hedgehog signaling and to inhibit tumor growth in medulloblastoma [50].  
 
 
1.5.3 E3 ubiquitin-protein ligases 
 
Ubiquitin-dependent proteolysis regulates protein abundance and serves as a central 
regulatory function in many biological processes.  
Ubiquitination is involved in a wide range of cellular functions, such as cell 
proliferation, differentiation, and apoptosis, mainly by targeting proteins for 
degradation by the proteasome, but it is also involved in protein transport and 
signaling through additional mechanisms.  
The ubiquitination of a target protein is mediated by the ubiquitin–protein ligases, 
which represent a diverse super-family of proteins and protein complexes. 
The largest known class of ubiquitin ligases is cullin- RING ubiquitin ligase such as 
Cul3, one of the seven cullins found in the human genome (Cul1, Cul2, Cul3, Cul4A, 
Cul4B, Cul5 and Cul7) (Figure 10). Most of them bind to adaptors through their BTB 
domains, which, in turn, bind to additional proteins that work as substrate-specific 
adaptors. In particular it was demonstrated that Cul3 interacts specifically with 
different KCTD proteins [51].  
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Figure 10. The common catalytic core of cullin–RING ligases, which consists of a RING protein 
and a cullin-family member, defines this modular class of ubiquitin ligase  
[Petroski, M.D., et al., Nat Rev Mol Cell Biol, 2005] 
 
 
Recent analyses have shown that the C-terminal region of KCTD5 is indispensable 
for interaction with Cul3, while the BTB/POZ domain interacts with additional five 
aminoacids on the N-terminal region. The Cul3 region involved in this interaction is 
the N-terminus, as described for other BTB/POZ proteins.  
More recently it has been demonstrated by co-immunoprecipitation experiments that 
also KCTD7 is able to homodimerize and to bind Cul3 like KCTD5, suggesting a 
similar mechanism of interaction [52]. 
KCTD11 also forms a multiproteins complex with Cul3 and HDAC mediating Gli 
deacetylation in Hedgehog (Hh) pathway [50]. Hedgehog is a master regulator of 
tissue development and its pathway deregulation is responsible for the onset of 
several tumors, including medulloblastoma. 
The relevant interest for KCTD11-Cul3 complex led to the study of molecular features 
governing the interaction.  
On the basis of molecular modeling studies and mutagenesis experiments [53], 
Pedone and co-workers proposed a model of KCTD11-Cul3 interaction derived from 
the structure of the known complex Skp1/Cul1 (Figure 11) [54], homologous of 
KCTD11 and Cul3, respectively.  
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Figure 11. Overall structure of the Cul1–Rbx1–Skp1–F box Skp2 quaternary complex.  
[Zheng, N., et al. Nature, 2002] 
 
 
 
In this model, each subunit of the tetramer of POZ/BTB domain interacts with a Cul3 
molecule, forming a complex of huge size which interacting with other fusion 
partners. Interestingly, the α-helix of the region 49-68 of Cul3 docks into a cavity 
formed at the inter-subunit interface within the tetramer. The analysis of the model 
also shows that, in this complex, a larger portion of the POZ/BTB domain is involved 
in the complex interface if compared to the 1:1 model. Indeed, each Cul3 molecule 
interacts with two distinct BTB subunits (Figure 12A). The residue Phe102 of 
KCTD11 directly interacts with a cluster of aromatic side chains of Cul3 made of 
Tyr58, Tyr62 and Tyr125 (Figure 12B). 
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Figure 12. (A) A view of the complex between the KTCD11 POZ/BTB tetramer with four 
molecules of Cul3 (red) and (B) a snapshot of the KTCD11 BTB-Cul3 interface [Correale, S., et 
al. Biochimie, 2011] 
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1.6 Aim of the work 
 
 
In the recent years the scientific community focused the attention on the design and 
synthesis of conformationally constrained molecules useful for development of new 
systems for biotechnological applications. 
The study of α-helical motifs occurring in PPI of some important molecular pathways 
was the starting point of this PhD thesis. The analysis of molecular features of the 
selected PPI allowed the design of peptide molecules able to mimic the structural 
motifs involved in these interactions. 
 
Malfunctions in transcriptional regulation are associated with many human diseases 
and there is considerable interest in developing artificial transcription factors (ATFs) 
that must minimally contain a DBD and a TAD.  
The ability to regulate the expression of any targeted gene using a ‘programmable’ 
ATF offers a powerful tool for functional genomics and for development of intriguing 
biotechnological systems. 
The p53 protein has a fundamental role in cellular survival due to its transcriptional 
activator function.  
Recently, structural studies obtained by NMR spectroscopy gave insights into 
interaction between p53 TAD2 and tfb1/p62 subunit of TFIIH and contributed to the 
understanding of the way p53 protein works in transcriptional activation. 
On the basis of this structure, the design and synthesis of molecules that mimic the 
helical fragment of p53 TAD2 and are able to bind tfb1 and to function as TADs were 
performed.  
It was hypothesized that peptides with increased helical propensity, which retain four 
key residues (IEXWF) in the α-helix of p53 TAD2 (residues 47 to 55 in p53) mimic 
p53 TAD2 and are stronger in vivo activators.  
Several peptides were designed by using different molecular tools such as N- and C-
capping boxes to enhance helical propensity. The peptides were synthesized on solid 
phase method and were analyzed by CD experiments to evaluate the helical content. 
ITC and NMR experiments allowed to demonstrate the interaction with tfb1 subunit of 
TFIIH. Subsequentally, studies in a yeast model system were performed to 
investigate the TAD properties of the obtained molecules.  
 
BTB/POZ domain-containing proteins are identified in diverse cellular locations and 
participate in different processes, ranging from transcriptional repression/activation to 
cytoskeletal organization.  
KCTD are a class of protein containing BTB/POZ domains with different biological 
functions, most of them unknown so far.  
KCTD11 was proposed as a suppressor of Hedgehog signaling and to inhibit tumor 
growth in medulloblastoma. POZ/BTB domain of this protein mediates interaction 
with Cul3, a protein that is associated to the class of ubiquitin ligases that induce 
proteolysis of target proteins by proteasome.  
The study of the molecular features governing the interaction of the Cul3 with 
KCTD11 could aid to understand the recognizing mechanism between KCTD family 
and proteasome machinery. These results could be used for the development of new 
entities able to work as agonist or antagonist of KCTD proteins involved in de-
regulated pathways. 
Recently, studies of molecular modeling and mutagenesis provided a model of 
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KCTD11-Cul3 interaction. On the basis of this information, the design and synthesis 
of peptides encompassing the Cul3 49-68 helical region involved in the interaction 
with KCTD11 were firstly performed. Subsequentially, an analogue containing 
hydrocarbon-bridge as molecular tool to stabilize helical conformation was 
synthesized. 
The conformation structure of all peptides was analyzed to estimate the helical 
content by CD experiments. The interaction with KCTD proteins were investigated by 
ELISA assays.  
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2. MATERIALS and METHODS 
 
 
2.1 Materials 
 
All amino acids, N-α-Fmoc-O-phospho-L-tyrosine, Rink-amide 4-
methylbenzhydrylamine (MBHA) and Novasyn TGR resin, HBTU, HOBt and HATU 
were purchased from Novabiochem. DIPEA, TFA, Piperidine, N-(+)-biotinyl-6-
aminocaproic acid, acetic anhydride and scavengers were supplied from Fluka. (S)-
N-Fmoc-2-(4'-pentenyl) alanine for stapled peptides synthesis was supplied from 
Anaspec. Grubb's catalyst for ring close metathesis (RCM) was supplied from Sigma-
Aldrich. The solvents used in the synthesis, purification and characterization of the 
peptides were purchased from Romil. 
Polypropylene reaction vessels and sintered polyethylene frits were supplied by 
Alltech Italia. 
All materials used for gene amplification were supplied by Stratagene Cloning 
Systems. All synthetic oligonucleotides were purchased from Sigma (Italy). All 
aqueous solutions were made using water purified by a Milli-Q water system 
(Millipore). All the chemicals used were of the highest grade available. 
Expression vector pETM11 and pETM20 were from Novagen.  
E. coli DH5α, E. coli BL21(DE3) codon plus RIL were purchased from Stratagene. 
BL21(DE3), BL21 (DE3)STAR strains were supplied by Invitrogen. The identity of the 
inserts in the resulting recombinant plasmids was confirmed by DNA sequencing 
(MWG-Biotech). 
 
2.2 p53 MIMETIC PEPTIDES 
 
This work has been carried out in collaboration with Prof. Omichinski at University of 
Montreal. In particular, expression and purification of protein and labeled peptides, 
NMR experiments and β-Galactosidase Activation Assay were performed at 
Biochemistry Department of University of Montréal. 
 
 
2.2.1 Peptides synthesis 
 
All peptides were obtained by Fmoc solid-phase strategy. The syntheses were 
carried out with Rink Amide MBHA resin (loading 0.63 mmol g-1), using all standard 
amino acids. The resin was swollen in DMF for 30 minutes prior to synthesis. 
Fmoc protecting group was removed by treatment with 30% piperidine in DMF (2 x 
10 min).  
Active ester-coupling reactions were performed under a 10-fold excess of amino acid 
respect with the resin and HBTU (9.8 equiv)/HOBT (9.8 equiv)/DIPEA (20 equiv) in 
DMF for 1 hour. The coupling efficiency was assessed by Kaiser test. Each step was 
followed by resin washings (3 x 5 min).  
Before cleavage from the resin, the peptides were acetylated by two treatments with 
a solution of acetic anhydride (0.5M) /DIPEA (0.015M)/HOBT (0.125M) in DMF for 10 
minutes. NC15, NC17 and p53-13 peptides were cleaved off the solid support by a 
solution of TFA/H2O/EDT/TIS (94.5:2.5:2.5:1 v/v/v/v) for 2 hours whereas A-Cap, E-
Cap, W-Cap peptides were cleaved off from the resin by treatment with 
TFA/H2O/EDT (90:5:5 v/v/v) for 2 hours. The resins were then filtered and the 
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peptides were precipitated using cold anhydrous diethyl ether.  
NC15, NC17 and p53-13 crude products were purified by preparative RP-HPLC at 
flow rate of 20 mL/min on a Shimadzu LC-8A system, equipped with a diode array 
detector SPD-10A, using a Phenomenex C18 column (21 x 250 mm; 15 µm; 300 Å). 
The binary solvent gradients chosen are different for each peptide: NC15 was 
purified with a linear gradient of H2O (0.1% TFA)/CH3CN (0.1% TFA) from 20 to 80% 
of CH3CN (0.1% TFA) in 30 min; NC17 with a linear gradient from 30% to 70% of 
CH3CN (0.1% TFA) in 30 minutes and p53-13 with a linear gradient from 30% to 80% 
of CH3CN (0.1% TFA) in 20 minutes. 
A-Cap, W-Cap and E-Cap peptides were purified using Ammonium Formate buffer 
0.1M (pH 7.0) and Ammonium Formate buffer/ CH3CN (pH 7.0) (1:1 v/v) with a linear 
gradient from 45% to 100% in 25 minutes for A-Cap, from 40% to 100% in 25 
minutes for W-Cap and from 50% to 95% of ammonium formate buffer/ CH3CN (pH 
7.0) in 30 minutes for E-Cap. 
The identity and purity of the peptides were assessed by LCQ Deca XP Max LC/MS 
system equipped with a diode array detector combined with an electrospray ion 
source and ion trap mass analyzer (Thermo Finnigan) using a Phenomenex C18 
column (250 x 2 mm; 5 µm; 300 Å) at flow rate of 200 µL/min. 
 
 
2.2.2 Circular Dichroism Studies 
 
Circular dichroism analysis were performed on a Jasco J-810 spectropolarimeter at 
25°C in 10 mM phosphate buffer at pH=7.1 using a quartz cell with a 0.1 cm path 
length in the 190–260 nm range. All peptide concentrations were determined by UV 
spectroscopy using A280. The results are reported as mean residue ellipticity [θ]. 
 
 
2.2.3 Isothermal Titration Calorimetry Studies 
 
The ITC experiments were performed in 20 mM TRIS (pH=7.5) for tfb1. The protein 
and peptides concentrations were determined from A280. All titrations were done at 
least in duplicates and were fit to a single binding site mechanism with 1:1 
stoichiometry. 
 
 
2.2.4 Cloning, Expression and Purification of peptides and recombinant 
 Proteins 
 
The bacterial expressed p53 peptide analogs, E-Cap, p53-13, p53-13(LL) and 
mutants were constructed by inserting the BamHI-EcoR1-digested DNA (IDT) into 
pGEX-2T plasmid. Tfb1 was cloned as described in [35]. Mutants of tfb1 were 
prepared using the QuickChange II site-directed mutagenesis kit (Stratagene). 
The p53 analogs and tfb1 were expressed as GST-fusion proteins in E. coli host 
strain TOPP2 and bound to GSH-resin (GE Healthcare) [35]. The resin bound protein 
was incubated overnight with thrombin (Calbiochem). After cleavage, the supernatant 
was purified by FPLC over a SP-Sepharose High Performance column. Uniformly 
(>98%) 15N-labeled and 15N/13C-labeled proteins were prepared in minimal media 
containing 15NH4Cl with or without 13C6-glucose as the sole nitrogen and carbon 
source. 
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2.2.5 Media, Plasmids and Strains 
 
All yeast strains were grown in synthetic complete media (SC; 0,67% yeast nitrogen 
base w/o amino acids, 2% glucose and amino acids drop-out mix) lacking uracil and 
histidine. The EGY48 (Mat alpha leu2-3 his3-11,15 trp1-1 ura3-1 6lexAops-LEU2) 
strain was transformed with the LexA operator-Lac-Z fusion plasmid pSH18-34 
combined with either pEG202NLS (pEG202 derivative with SV40 nuclear localization 
sequence between LexA and polylinker) as a negative control, pSH17-4 (GAL4-
activation domain cloned into pEG202 backbone) as a positive control or 
pEG202NLS with LexA fused to the activation domains to be tested. 
 
 
2.2.6 β-Galactosidase Activation Assay 
 
Yeast strains were transformed with the LexA operator–lacZ fusion plasmid pSH18–
34 (eight LexA binding sites) and various LexA-fusion proteins to determine the 
relative abilities of the fusion proteins to activate transcription in the yeast model 
system. In all cases, cells were grown to mid-logarithmic phase in growth media 
lacking Ura and His. The number of cells used for the various LexA fusion proteins 
was adjusted to obtain reliable readings of optical density at 420 nm. For each 
measurement, β-galactosidase activity was determined from three independent 
cultures and average values are given. One unit of β-galactosidase is defined as the 
amount that hydrolyzes 1 µmol of ONPG to o-nitrophenol and galactose per minute 
per cell. Results are presented as the mean of the percentages of the β-
galactosidase units of the tested peptides on the β-galactosidase units of the GAL4 
positive control ± standard error of the mean (SEM). Western blot analysis was 
performed with an anti-LexA antibody to verify expression of all LexA-fused peptides. 
 
 
2.2.7 NMR Samples 
 
For the NMR chemical shift mapping studies with labeled Tfb1PH, the samples 
consisted of 0.5 mM 15N-Tfb1PH in 20 mM sodium phophate (pH=6.5), 1 mM EDTA 
and 90% H2O/10% D2O; unlabeled p53 analogs (NC17, NC15, E-Cap, W-Cap or A-
Cap) were added to a final ratio of 1:2. For the chemical shift mapping studies with 
labeled E-Cap peptide, the sample consisted of 0.5 mM of 15N-E-Cap in 20 mM 
sodium phosphate (pH=6.5), 1 mM EDTA and 90% H2O/10% D2O to which unlabeled 
tfb1 was added to a final ratio of 1:2. For the competition experiment, an HSQC was 
first collected with a sample containing 0.8 mM of 15N-p5340-73 (p53TAD2) in 20 mM 
sodium phosphate (pH=6.5), 1.0 mM EDTA and 90% H2O/10% D2O. Then 1 mM of 
unlabeled tfb1 was added and a second HSQC was collected. 
Finally, 0.8 mM of unlabeled E-Cap peptide was added and a third HSQC spectrum 
was recorded. The structural studies of the E-Cap peptide in complex with tfb1 were 
performed on two samples. The first contained 0.5 mM of 15N-E-Cap and 0.5 mM 
unlabeled tfb1 in 20 mM sodium phosphate (pH=6.5), 1 mM EDTA and 90% 
H2O/10% D2O. The second sample contained 0.5 mM 15N/13C-Tfb1PH and 0.5 mM 
unlabeled E-Cap in 20 mM sodium phosphate (pH=6.5), 1 mM EDTA. For studies in 
D2O, the sample was dissolved in 99.996% D2O. 
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2.2.8 NMR Spectroscopy Experiments 
 
The NMR experiments were carried out at 295 K on Varian Unity Inova 500, 600 and 
800 MHz spectrometers. For the chemical shift mapping studies, 2D 1H-15N HSQC 
were recorded. Intramolecular nuclear Overhauser effects (NOEs) for E-Cap were 
obtained from 3D 15N-edited NOESY-HSQC (τm=140 ms) and 2D 13C/15N-{F1/F2}-
filtered 1H-1H NOESY (τm=40 and 100 ms). The NMR data were processed with 
NMRPipe/NMRDraw and analyzed with CcpNmr. 
The NOE-derived distance restrains were divided into four classes defined as strong 
(1.8-2.8 Å), medium (1.8-3.4 Å), weak (1.8-5.0 Å) and very weak (3.3-6.0 Å). 
Backbone dihedral angles were derived with the program TALOS. The structure of E-
Cap was calculated using the program CNS, with a combination of torsion angle and 
Cartesian dynamics and starting from an extended structure with standard geometry. 
The quality of structures was assessed using PROCHEK-NMR and MOLMOL. The 
figures were generated with the program PyMol (http://www.pymol.org). 
 
 
2.3 Cul3 MIMETIC PEPTIDES 
 
The expression and purification of KCTD11 protein has been carried out in 
collaboration with Dr. Emilia Pedone and Dr. Sonia Di Gaetano at IBB-CNR of 
Naples.  
 
2.3.1 Peptide syntheses 
 
Cul3wt, Cul3Y(P) and stapled Cul3 peptides encompassing the region 49-68 of 
Cullin3 sequence were obtained by Fmoc solid-phase strategy [Table xx]. To mimic 
the charge status of the fragment within the parent protein, the N-terminus and the C-
terminus of the peptides were acetylated and amidated, respectively. The syntheses 
were carried out with Novasyn TGR resin (substitution 0.24 mmol g-1), using standard 
amino acids except N-α-Fmoc-O-phospho-L-tyrosine for Cul3Y(P) and (S)-N-Fmoc-
2-(4'-pentenyl) alanine for stapled peptides synthesis. 
The resin was swollen in DMF for 30 min prior to synthesis. Coupling reactions for 
standard amino acids were performed by using 10 equivalents of Fmoc protected 
amino acids respect with the resin activated in situ with HBTU (9.8 equiv)/HOBt (9.8 
equiv)/DIPEA (20 equiv) in DMF for 1 h.  
Coupling reactions of N-α-Fmoc-O-phospho-L-tyrosine were instead performed by 
using 5 equivalents of amino acid activated in situ with PyBop (5 equiv)/DIPEA (10 
equiv) in DMF overnight. 
Coupling reactions of (S)-N-Fmoc-2-(4'-pentenyl) alanine were performed by using 2 
equivalents of amino acid activated in situ with HATU (1.9 equiv)/DIPEA (4 equiv) in 
DMF overnight. 
The coupling efficiency was assessed by Kaiser test. Each step was followed by 
resin washings (3 x 5 min). 
Fmoc protecting group was removed by treatment with 30% piperidine in DMF two 
times for 10 minutes. Before the cleavage from the resin, all the peptides were 
acetylated or biotinylated at N-terminus to obtain the corresponding derivatives. The 
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acetylation reaction was carried out two times for 10 minutes using a solution of 
acetic anhydride (0.5 M)/DIPEA (0.015 M)/HOBt (0.125 M) in DMF.  
Biotinylated peptides were obtained using a solution of N-(+)-biotinyl-6-aminocaproic 
acid (2 equiv)/HATU (1.9 equiv)/DIPEA (4 equiv) in DMF overnight. 
The metathesis reactions were performed on aliquotes of peptidyl-resins containing 
acetylated or biotinylated peptides by treatment with a solution of Grubb's catalyst 
0.1M (1st generation) in DCM, 2 times for 2 hours. 
Cul3-wt and Cul3-Y(P) peptides were cleaved off the resin by treatment with a 
mixture of TFA/H2O/EDT/TIS (94: 2.5: 2.5: 1 v/v/v/v) for 2 hours at room temperature, 
while Cul3 stapled peptides were cleaved off the resin by treatment with a mixture of 
TFA/H2O/EDT/Thioanisole/Phenol (82,5: 5: 2.5: 5: 5 v/v/v/v).  
The resins were filtered and the crude peptides were precipitated with diethyl ether, 
dissolved in a H2O/CH3CN (1: 1) solution and lyophilized. The peptides were purified 
by preparative RP-HPLC on the Shimadzu system equipped with a UV-Vis detector 
SPD10A using a Phenomenex Jupiter Proteo C12 column (21.2 x 250 mm; 4 µm; 90) 
and a linear gradient of H2O (0.1% TFA)/CH3CN (0.1% TFA) from 20 to 70% of 
CH3CN (0.1% TFA) in 20 min at flow rate of 5 ml/min. The collected fractions 
containing the peptides were lyophilized.  
The identity and purity of the peptides were assessed by an ESI-LC-MS instrument 
(ThermoFinnigan, NY, USA) equipped with a diode array detector combined with an 
electrospray ion source and ion trap mass analyzer using a Phenomenex Jupiter 
Proteo C12 column (150 x 2 mm; 4 µm; 90 Å) and a linear gradient of H2O (0.1% 
TFA)/CH3CN (0.1% TFA) from 20 to 80% of CH3CN (0.1% TFA) in 20 minutes at flow 
rate of 200 µl/min. 
 
 
2.3.2 Circular Dichroism Studies 
 
Circular dichroism analysis were performed on a Jasco J-810 spectropolarimeter at 
25°C in 10 mM phosphate buffer at pH=7.1 using a quartz cell with a 0.1 cm path 
length in the 190–260 nm range. All peptide concentrations were determined by UV 
spectroscopy using A280. The results are reported as mean residue ellipticity [θ]. 
 
 
2.3.3 Expression and Purification of POZ/BTB domains of KCTD11 
 
After a first screening of small-scale expression cultures, performed using different 
strains, temperatures, IPTG concentration and induction length, recombinant 
constructs were transferred into E. coli strain that assured the best expression level 
in soluble phase. 
Cell pellets from 500 ml cultures were re-suspended in 10 ml of 20 mM Tris/HCl pH 
7.5 (buffer A), supplemented with a protease inhibitor cocktail (Complete EDTA-
FREE, Roche). Crude extracts were prepared by disrupting the cells with 10 min 
pulses at 20 Hz (Misonix Sonicator 3000) and centrifugating lysates at 16 000 rpm for 
30 min. The crude extracts were applied on a HisTrap HP (GE Healthcare) 
equilibrated with buffer A containing 0.3 M NaCl and 10 mM imidazole. Proteins were 
eluted with the same buffer A supplemented with 300 mM imidazole.  
For KCTD11 the active fractions were pooled, extensively dialyzed against 50 mM 
Tris/HCl pH 7.5, 0.5 mM EDTA and successively digested with the protease TEV 
(Tobacco Etch Virus). The digested samples were applied onto a HisTrap performed 
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as above described. The flow-through samples were applied onto a 1.6 cm _ 60 cm 
column (HiLoad Superdex 200, GE Healthcare) connected to an AKTA system 
(GE Healthcare) and eluted with Buffer A containing 0.15 M NaCl. 
at a flow rate of 1 ml/min. 
 
 
2.3.4 ELISA Assays for Cul3 peptides 
 
For ELISA assays, 5 µg/ml streptavidin in phosphate/citrate buffer pH 5.0 was 
incubated overnight at 37°C for coating. First, binding was executed with 0.8 µM 
biotinylated Cul3 peptides in Phosphate Buffered Saline (PBS) 1X for 1 h at room 
temperature. Second, binding was performed with different concentrations of His- 
TrxA/KCTD11 BTB (0.8, 1.5, 3.8, 7.6 and 15.6 µM) in PBS 1X. His-TrxA was used as 
negative control in the same concentrations. As blocking solution 1% BSA, 0.05% 
Tween-20 in PBS 1X was used for 1 h at room temperature. To reveal the occurred 
interaction mouse anti-His monoclonal antibody was incubated in 1: 1000 dilution at 
room temperature for 2 h; then, horseradish peroxidase-conjugated anti-mouse 
antibody (Pierce) was diluted 1:10 000 in PBS 1X and incubated at room temperature 
for 1 h. The colorimetric reaction has been carried out with SIGMAFAST OPD 
reagent (Sigma Aldrich), according to the manufacturer’s instructions. Finally, a 
Model680 Microplate Reader (Bio-Rad, Hercules, CA-USA) has been used for 
readings at 490 nm; data were processed by a Microplate Manager 5.2 program. The 
reported data are mean values of triplicate experiments. 
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3. RESULTS 
 
 
3.1 p53 Mimetic Peptides 
 
The design of peptides that mimic the properties of p53 TAD2 as transcriptional 
activator was based on information obtained by NMR structure of tfb1/TAD2 
complex. This study highlighted that the helical region of p53 TAD2 between residues 
47-55 contains the structural features for binding with tfb1/p62 subunit of TFIIH. 
Since the residues Ile51, Glu52, Trp53 and Phe54 in the α-helix of TAD2 are 
fundamental for the interaction, the design strategy consisted of keeping fixed the 
three dimensional conformation of these residues and of introducing molecular tools 
to stabilize the helical secondary structure.  
 
 
3.1.1 Design of the first generation of peptides: p53-13, NC15 and NC17  
 
Three peptide sequences named p53-13, NC17 and NC15 were designed. The helix 
conformation of these peptides was stabilized by using N- and C-capping sequences. 
These motifs are defined as specific patterns found at or near the ends of helices 
that, involving hydrogen bonding and hydrophobic interactions, increase the helical 
propensity of a peptide sequence.  
The residues at the N-terminal of an α-helix are indicated as N'-Ncap-N1-N2-N3-N4. 
Ncap is the residue with non helical ϕ and ψ angles immediately preceding the N-
terminus and N1 is the first residue with helical ϕ and ψ angles. Similarly, the C-
terminal residues are defined as C4-C3-C2-C1-Ccap-C'-C" [10], [55].  
N-terminal capping box is a motif where the side chain of the Ncap residue forms a 
hydrogen bond with the backbone of N3 and the side chain of N3 forms a hydrogen 
bond with the backbone of Ncap [10], [55].  
The Schellman motif has two backbone-backbone hydrogen bonds between the 
amide NH at C" and the carbonyl group at C3 and between amide group at C' and 
the carbonyl group at C2. The associated hydrophobic interaction is between C3 and 
C" while polar residues are highly favored at C1 position. The C' residue is typically a 
glycine [10], [55]. 
p53-13 peptide encompasses the 45-57 sequence of p53 protein without N- and C-
capping motifs (Table 1). This sequence was chosen as peptide reference to 
evaluate the effect of the helical stabilization on the biological activity.  
NC17 peptide consists of 17 amino acids and preserves the 50-54 sequence of p53 
except for the Gln52 that was replaced with Glu to favour the stabilization of the helix 
by the i, i+4 salt bridge with Lys at C-terminal region (Table 1). NC17 contains the N-
capping box and Schellman motif at C-terminal region [55] whose residues were 
chosen according to the frequency of occurrence in the corresponding box positions. 
In particular in the capping motif it was preferred to retain Asp48 present in the native 
sequence instead of inserting Glu as reported. 
NC15 peptide contains 15 residues encompassing the 50-54 sequence of p53 and 
the N-capping box of NC17 (Table 1). In this case Schellman motif at C-terminal 
region includes Trp54 and Phe53 residues directly involved in the tfb1 interaction and 
the stabilization of the helix by the i, i+4 salt bridge involves Glu51 and Lys at C-
terminal region.  
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All peptides were acetylated and amidated at the N- and C-termini respectively, to 
avoid the interference of terminal charges with helix dipole and their sequences are 
reported in Table 1. 
 	  
Table 1 
Peptide Sequence
p53-13      Ac-45Leu-Ser-Pro-Asp-Asp-50Ile-Glu-Gln-Trp-Phe-55Thr-Glu-Asp-NH2 
NC17 Ac-Leu-Thr-Pro-Asp-Glu-Phe-Ile-Glu-Glu-Trp-Phe-Leu-Lys-Asp-His-Gly-Ile-NH2 
NC15     Ac-Leu-Thr-Pro-Asp-Glu-Phe-Ile-Glu-Gln-Trp-Phe-Lys-His-Gly-Ile-NH2  
Red Line Key residues for interaction with Tfb1 
Blu Line N-Capping motif residues 
Green Line Schellman motif residues  
 
 
 
3.1.2 Synthesis of p53-13, NC15 and NC17 Peptides 
 
The peptides were synthesized by Fmoc solid phase strategy. The identity and purity 
of the obtained peptides were assessed by LC-MS (Figure 18, 19, 20). The synthesis 
yields theoretical masses and molecular ion peaks for peptides were reported in 
Table 2. 
 
 
Table 2 
Peptide Yield (%) Theoretical Mass (Da) Molecular ion peak 
p53-13 27,5 1635.7 1635,0 
NC15 13,5 1901,2 1901,4 
NC17 50 2130,4 2131,0 
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Figure 13. (A) LC-MS of p53-13, (B) of NC15 and (C) NC17. 	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3.1.3 CD studies 
 
The conformational behavior of synthesized peptides was investigated by circular 
dichroism experiments (Figure 14). 
CD spectrum of p53-13 peptide is characterized by a deep minimum at 200 nm 
peculiar of a peptide without a secondary structure conformation. 
CD spectrum of NC17 peptide is characterized by two minima at 202 and 221 nm 
without crossover corresponding to a poor content of helical conformation while the 
NC15 spectrum shows two minima at 220 and 206 nm and a crossover at 199 nm 
typical of a peptide with some helical content. 
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Figure 14. CD Spectra of p53-13 (red line), NC15 (green line) and NC17 (pink line) peptides. 
 
 
The analysis of data obtained by CD experiments (Table 3) highlighted that the ratios 
between the CD signal at 222 nm and the signal of the other minimum at lower 
wavelength, which is often used as a mean to confirm the presence of helical content 
[56] are 0.24, 0,73 and 0,58 for p53-13, NC15 and NC17 peptides, respectively. 
These values indicate that the introduction of N-capping box and Schellman motif in 
the peptides improve the α-helix content respect with p53-13. 
 
 
Table 3 
Peptide θ222 θmin θ222/θmin θ190 cross 
p53-13 -2486 -10422 0,239 -3405 187 
NC15 -7008 -9538 0,735 5979 198 
NC17 -5522 -9421 0,586 -46 189 
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3.1.4 ITC Experiments 
 
The ability of obtained peptides to bind tfb1 was tested by ITC experiments. p53-13 
peptide displayed an apparent dissociation constant (Kd) of 1,6±0,3 µM for the 
interaction with tfb1. On the contrary, ITC experiments indicated that neither NC15 
nor NC17 are able to bind tfb1 under the same conditions. 
 
 
3.1.5 NMR Experiments 
 
2D 1H-15N HSQC spectra of 15N-labeled tfb11-115 in the free form and in the presence 
peptides respectively were performed. Several residues of p53-13 undergoing 
dramatic changes in 1H and 15N chemical shifts are identical to those observed with 
p53 (20-73) protein in complex with tfb11-115 (Figure 15). The residues that showed 
the most significant changes in 1H and 15N chemical shifts upon formation of the 
complex are located in the region of strands β5, β6, β7 and loop between β5/β6 of 
tfb1 structure.  Unfortunately NC15 and NC17 have not shown a good KD while p53-
13 has shown a higher binding affinity in comparison with its cognates. 
Although the addition of a N-capping box and a C-capping box increases the helical 
propensity, both NC15 and NC17 possess significantly lower affinity for tfb1 than 
p53-13. 
 
 
 
Figure 15. Overlay of the 2D 1H-15N-HSQC spectra of 15N-labeled Tfb1 in the free form (black) 
and in the presence of p53-13 (red). 
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3.1.6 Design of the second generation of peptides: N-Cap series  
 
A second generation of molecules referred as E-Cap, W-Cap and A-Cap was 
designed in which the C-capping motif was not included. 
In these peptides a N-capping motif was combined with a hydrophobic bridge that 
involve the side chains of two leucines. These residues were inserted in positions 6 
and 9 with i, i+3 spacing so that the hydrophobic interaction would form in the center 
of the peptide, but on the opposite face of the α-helix relative to the tfb1-binding 
interface. This approach is similar to VEGF mimetic peptide (QK) design [57].  
The three peptides are all 13 residues long and differ only for N-capping motif 
composition. The sequences are reported in Table 4. 
In E-Cap peptide Glu at N1 was selected for its high frequency of occurence in the 
capping box [55] and for its acidic features mimicking the phosphorylation at Ser 46 
in the native protein. 
In W-Cap Trp was chosen for homology with the QK-peptide and in A-Cap Ala was 
selected since it is present in this position in VP16, the activator transcriptional factor 
of Herpes Simplex virus that share the same binding interface of p53 TAD2 on tfb1 
[37]. 
 
 
Table 4 
Peptide Sequence
E-Cap Ac-Leu-Thr-Glu-Glu-Glu-Leu-Ile-Glu-Leu-Trp-Phe-Thr-Glu-NH2 
A-Cap Ac-Leu-Thr-Ala-Glu-Glu-Leu-Ile-Glu-Leu-Trp-Phe-Thr-Glu-NH2  
W-Cap Ac-Leu-Thr-Trp-Glu-Glu-Leu-Ile-Glu-Leu-Trp-Phe-Thr-Glu-NH2  
Red Line Key residues for interaction with Tfb1 
Blu Line N-Capping mutant residues 
Green Line Leucine for i, i+3 hydrophobic bridge residues  
 
 
3.1.7 Synthesis of A-Cap, W-Cap and E-Cap peptides 
 
The peptides were synthesized by Fmoc solid phase strategy. The purification of N-
Cap peptides required different conditions compared to the standard methods 
because of the high content of acidic residues and poorly solubility in acid solution.  
The purified peptides (99%) were analyzed by LC-MS (Figure 23,24,25). The yields, 
theoretical masses and ion molecular peaks are reported in Table 5. 
 
 
Table 5 
Peptide Yield (%) Theoretical Mass (Da) Molecular ion peak 
E-Cap 16,7 1692,9 1693,4 
A-Cap 20,8 1634,8 1635,5 
W-Cap 18,4 1750,0 1751,4  
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Figure 16. LC-MS (A) of E-Cap, (B) of A-Cap and (C) W-Cap 
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3.1.8 CD studies 
 
The structural properties of E-Cap, A-Cap and W-cap peptides were analyzed by CD 
experiments (Figure 17). 
The shape of the obtained CD spectra is very like, highlighting similar content of α-
helix structure. 
 
-20 
20 
-10 
0 
10 
190 260 200 220 240 
Wavelength [nm] 
[θ
] (
10
-3
 d
eg
 c
m
2 
/d
m
ol
e)
 
E-Cap 
W-Cap 
A-Cap 
	  
Figure 17. CD Spectra of E-Cap (blue line), W-Cap (red line) and A-Cap (green line) 
 
 
The ratios between the CD signal at 222 nm and the signal of the other minimum at 
lower wavelength are 0.52, 0,54 and 0,52 for E-Cap, A-Cap and W-Cap, respectively. 
A comparison with the CD spectra of first generation peptides clearly indicates an 
increase of the secondary structure compared to p53-13 but a reduction of helical 
content compared to NC15. 
 
 
Table 6 
Peptide θ222 θmin θ222/θmin θ190 cross 
E-Cap -6983 -13359 0,523 4217 193 
A-Cap -7135 -13112 0,544 7669 194 
W-Cap -7227 -13790 0,524 17409 197 
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3.1.9 ITC Experiments 
 
All the peptides were able to bind tfb1 as verified by ITC experiments. In particular E-
Cap peptide has an apparent Kd of 0.24 ± 0.03 µM while A-Cap and W-Cap have an 
apparent Kd values of 1.3 ± 0.1 µM and 1.9 ± 0.3 µM respectively, similar to p53-13. 
 
 
3.1.10 NMR Experiments 
 
NMR titration experiments were performed to determine the binding site of the N-Cap 
peptides on tfb1.  
Addition of E-Cap to 15N-labeled tfb1 produced changes in both the 1H and 15N 
chemical shifts for several signals in the 1H-15N-HSQC spectrum of tfb1 (Figure 19). 
As p53 TAD2, a mapping on the structure of tfb1 have highlighted that most 
significant changes of signals of the residues are located within the strands β5, β6 
and β7 and in the loop between β5 and β6. 
Similar changes in chemical shifts are also observed in titrations of tfb1 with both A-
Cap (Figure 20) and W-Cap (Figure 21) but with lower intensity than E-Cap. 
So the introduction of N-capping box and dileucine hydrophobic bridge increases the 
α-helix content of all three peptides but improves the affinity mostly of E-Cap for tfb1. 
Although CD studies indicate that E-Cap possesses a higher helical content than 
p53-13, NMR experiments with E-Cap did not show the presence of NOE signals 
characteristic of an α-helical conformation in the free form. Additional NMR studies of 
E-Cap in complex with tfb1 show that like p53 TAD2, it transitions to form a nine-
residue α-helix from Glu3 to Phe11 (Figure 18). The structure of E-Cap in complex 
with tfb1 confirms that the side-chains of Leu6 and Leu9 are in close proximity to 
each other, and on the opposite side of the helix relative to the binding interface with 
tfb1. 
In addition, the side-chain of Leu6 is in position to further stabilize the helix through 
contacts with the aromatic ring of Trp10 in the i+4 position. 
 
 
  
W10 
L9 
L6 
F11 
I7 	  
Figure 18. Ribbon model of the average structure of the E-Cap peptide from the complex with 
Tfb1PH. The side chains of the three hydrophobic residues (I7, W10 and F11) and the leucines 
(L6 and L9) are highlighted to show that they are on opposite faces of the helix 
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Figure 19. Overlay of the 2D 1H-15N-HSQC spectra of 15N-labeled tfb1 in the free form (black) 
and in the presence of 0.5 (blue), 1.0 (green) and 1.25 (red) equivalents of E-Cap 
 
 
 
 
 
Figure 20. Overlay of the 2D 1H-15N-HSQC spectra of 15N-labeled Tfb1 in the free form (black) 
and in the presence of 0.5 (blue), 1.0 (green) and 1.25 (red) equivalents of A-Cap 
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Figure 21. Overlay of the 2D 1H-15N-HSQC spectra of 15N-labeled tfb1 in the free form (black) 
and in the presence of 0.5 (blue), 1.0 (green) and 1.25 (red) equivalents of W-Cap 
 
 
3.1.11 E-Cap in vivo experiment 
 
The potential ability of E-Cap to activate transcription in vivo was investigated in 
yeast cells. E-Cap sequence was expressed fused to the DNA-binding domain (DBD) 
of LexA and its activity was measured for the lacZ reporter gene relative to a positive 
control (Gal4-TAD/LexA-DBD) whose activity is established as 100 %. 
In this system, the E-Cap-LexA-DBD fusion protein activates transcription at 161 ± 9 
% of the positive control. In comparison, the native p53-13 peptide fused to the LexA-
DBD activates transcription at only 8 ± 3 %. Thus, E-Cap is ~20 fold more potent 
than p53-13 as a transcriptional activator in this in vivo system. 
To compare the in vivo activity of the E-Cap relative to other known artificial TADs, its 
activity relative to two models artificial TADs, the AH 47 and VP2 45 peptides was 
compared. The AH-LexA-DBD and VP2-LexA-DBD activates transcription at 
approximately 5% of the positive control (Figure 22) which is similar to p53-13, but 
over 30-fold less than E-Cap. These results strongly support the idea that stabilizing 
the helical character of short analogs of p53 TAD2 can lead to a significant 
enhancement of their in vivo transcriptional activity. 
To investigate the role of two leucine residues in i, i+3 positions to activate the 
transcriptional in vivo, the leucine residue at position 9 was mutated to native 
glutamine residue found in p53-13 to generate E-Cap-(LQ). This change lowers the 
in vivo activity to 67 ± 8 % of the positive control, and thus E-Cap-(LQ) is ~50% less 
active than E-Cap. 
Next, two leucine residues were inserted at equivalent positions of p53-13 to 
generate p53-13-(LL). The in vivo transcriptional activation of p53-13-(LL) is 10-fold 
higher than p53-13, but 50% less active than E-Cap. These results support the idea 
	   49	  
that both the N-Cap motif, and the dileucine-bridge contribute significantly to the in 
vivo transcriptional activity of E-Cap. 
Experimental and theoretical studies indicate that two hydrophobic amino acids 
separated by either three (i, i+3 spacing pattern) or four residues (i, i+4 spacing 
pattern) enhance the helical propensity of peptides through side-chain interactions. 
Therefore since the insertion of the two leucines with an i, i+3 spacing pattern 
enhances the in vivo activation of E-Cap and p53-13-(LL), the role of leucines with an 
i, i+4 spacing pattern on in vivo activity was also tested. 
Leucine residues were introduced at positions 4 and 8 in the p53-13 peptide 
generating p53-13-(LL4) and at positions 5 and 9 in the E-Cap peptide E-Cap-(LL4). 
These positions are again chosen in an attempt to place the leucine bridge in the 
center of the peptide, but on the backside of the helix relative to the Tfb1PH binding 
interface. In the yeast activation assay, LexA-p53-13-(LL4) displays 51 ± 8 % of the 
activity of GAL4-LexA. This corresponds to a 6-7-fold increase in activity compared to 
the native p53-13 (8 ± 3%), but only about half of the activity that we observe when 
the leucines are in the i, i +3 spacing pattern in p53-13-(LL) (95 ±6 %). Similarly, E-
Cap-(LL4) displays 60 ± 2 % of the activity of GAL4-LexA, but this corresponds to 
roughly 40% of the activity compared to E-Cap-(LL) (161 ± 9 %). The increased in 
vivo activity observed when two leucines were inserted in either the i, i+3 or i, i+4 
spacing pattern of p53-13 is consistent with in vitro studies with model peptides 
showing that both spacing patterns are able to increase their helical 
propensity/stability. 
In conclusion, these results strongly support the idea that stabilizing the helical 
character of short analogs of p53 TAD2 can lead to a significant enhancement of 
their in vivo transcriptional activity. 
 
Ga
l4 
p5
3-1
3 
E-
Ca
p 
AH
/VP
 
p5
3-1
3(L
L) 
p5
3-1
3(L
L4
) 
E-
Ca
p(L
Q)
 
E-
Ca
p(L
L4
) 
100 
8 
161 
5 
95 
51 
67 60 
	  
Figure 22. LexA-peptide fusion proteins were co-transformed into yeast with the reporter LexA 
operator-Lac-Z fusion plasmid pSH18-34. Results are presented as the mean of the 
percentages of the β-galactosidase units of the tested fusion proteins on the β-galactosidase 
units of the LexA-GAL4TAD positive control 	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3.2 Cul3 Mimetics 
 
3.2.1 Design of Cul3-wt, Cul3-KK & Cul3-Y(P)  
 
The studies of complex between Cul3 and BTB/POZ domain of KCTD11 by 
molecular modeling and mutagenesis studies [50], [53] highlighted that the 
interaction is stabilized by a cluster of aromatic residues Tyr58, Ty62 and Tyr125 
located in the helix 55-65 of the Cul3 and Phe102 and Tyr103 of KCTD11. It was 
shown that mutations of these residues inhibit the formation of the complex. Although 
other Cul3 residues are involved in KCTD11 recognition, the attention was focused 
on the role played by the sequence mentioned above.  
A Cul3-based peptide as a potential KCTD11 binder was therefore designed by 
considering the peptide corresponding to the 49–68 region in Cul3 sequence (named 
Cul3-wt hereafter). The location of this fragment within Cul3 three-dimensional 
structure is shown in Table 7. 
To check the role of aromatic side chains in Cul3 – KCTD11 complex model, a Cul3-
wt peptide analogue (Cul3-KK) in which Tyr58 and Tyr62 were substituted with Lys 
residues was also designed. 
Cul3 is a target for tyrosine kinase and recently it was highlighted that Tyr58 is a site 
of phosphorylation in some cancer cell lines [58]. To verify the effect of this 
phosphorylation on binding with KCTD11, Cul3-Y(P) peptide was designed. This 
peptide preserves the same sequence of Cul3-wt peptide with Tyr(PO3H2) in place of 
Tyr58. 
 
 
Table 7 
Peptide Sequence
Cul3-wt Ac-49Asn-Ser-Gly-Leu-Ser-Phe-55Glu-Glu-Leu-Tyr-Arg-60Asn-Ala-Tyr-Thr-Met-65Val-Leu-His-Lys-NH2!
Cul3-KK Ac-Asn-Ser-Gly-Leu-Ser-Phe-Glu-Glu-Leu-Lys-Arg-Asn-Ala-Lys-Thr-Met-Val-Leu-His-Lys-NH2!
Cul3-Y(P) Ac-Asn-Ser-Gly-Leu-Ser-Phe-Glu-Glu-Leu-Tyr(P)-Arg-Asn-Ala-Tyr-Thr-Met-Val-Leu-His-Lys-NH2!  
Red Line Tyrosine key residues for POZ/BTB-Cul3 interaction 
Green Line Lysine mutant residues 
Blue Line Tyr phosphorylated residue 
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3.2.2 Synthesis of Cul3-wt, Cul3-KK and Cul3-Y(P) 
 
The peptides were synthesized by Fmoc solid phase strategy. All peptides were also 
obtained as biotinylated analogues for the following ELISA assays. 
The identities and the purities (99%) of peptides were assessed by LC-MS. The 
yields, the theoretical masses and ion molecular peaks are reported in Table 8. 
 
 
Table 8 
Peptide Yield (%) Theoretical Mass (Da) Molecular ion peak [M + 2H]2+ 
AcCul3-wt 21 2413,7 2411,6 
BiotinylCul3-wt 20,4 2709,3 2708,0 
AcCul3-Y(P) 32,4 2492,2 2492,0 
BiotinylCul3-Y(P) 29,7 2789,3 2786,6 
AcCul3-KK 17,5 2343,7 2345,6 
BiotinylCul3-KK 13,2 2639,4 2640,9  
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Figure 23. LC-MS (A) of Cul3-wt and (B) of BiotCul3-wt 	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Figure 24. LC-MS (A) of  Cul3-Y(P) and (B) of BiotCul3-Y(P) 	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Figure 25. LC-MS (A) of Cul3-KK (B) of BiotCul3-KK 	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  3.2.3 CD Studies	  
 
The CD spectra of Cul3-wt and Cul3-KK are similar and show a deep minimum at 
~202–203 nm, a second minimum at ~222 nm, a cross over at ~192–193 nm, and a 
maximum at a wavelength lower than 190 nm (Figure 26). The general features of 
the both spectra are indicative of a low helical content [59].  
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Figure 26. CD spectra of Cul3-wt (green line) and Cul3-KK (red line) 
 
 
The analysis of data obtained by CD experiments (Table 9) highlighted that the ratios 
between the CD signal at 222 nm and the signal of the other minimum at lower 
wavelength are 0.49 and 0.42 for Cul3-wt peptide and Cul3-KK peptide, respectively. 
These values confirm that these peptides possess low helical contents. 
 
 
Table 9 
Peptide θ222 θmin θ222/θmin θ190 cross 
Cul3-wt -4599 -9283 0,495 1146 192 
Cul3-KK -5560 -13190 0,422 4338 193 
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3.2.4 ELISA Assay 
 
The ELISA assays were performed with biotinylated Cul3-wt, Cul3-KK and Cul3-Y(P) 
and KCTD11-Trx fused protein. Trx protein used as negative control.  
The shape of the binding curve (Figure 27) shows that Cul3-wt peptide is able to bind 
to KCTD11 with a higher affinity than Cul3-KK and Cul3-Y(P) peptides [59].  
These results could confirm the importance of Tyr58 and Tyr62 residues in the 
interaction in accordance with molecular modeling studies.  
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Figure 27. Binding curves obtained from ELISA assays on the proteins KCTD11 using the 
peptides BiotinCul3-wt  (blue line), BiotinCul3-KK (yellow line) and BiotinCul3-Y(P) (pink line) 
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3.2.5 Design of Cul3-stapled peptides 
 
With the aim to test the effect of the enhancement of the helical content of Cul3 
analogues on binding affinity with KCTD11, two further peptides were designed: a 
cyclic peptide containing a hydrocarbon bridge in the center of native sequence of 
Cul3-wt peptide (Cul3-stapled) and its linear analogue (Cul3-stapline). The bridge 
was inserted substituting Leu57 and Ala61 located at the center of putative α-helix of 
Cul3 with two 2(S)-(4'- pentenyl) alanine (S5) residues. The metathesis reaction by 
Grubb's catalyst allowed the formation of this hydrocarbon bond between the two C4' 
of side chains of the α,α-disubstituted amino acids.  
Cul3-stapled and Cul3-stapline peptides were synthesized in acetylated and 
biotinylated forms to analyze both conformational character and ability to bind 
KCTD11 by ELISA assay, respectively.  
 
 
Table 10 
Peptide Sequence
Cul3-stapline Ac-Asn-Ser-Gly-Leu-Ser-Phe-Glu-Glu-S5-Tyr-Arg-Asn-S5-Tyr-Thr-Met-Val-Leu-His-Lys-NH2!
Cul3-stapled Ac-Asn-Ser-Gly-Leu-Ser-Phe-Glu-Glu-S5-Tyr-Arg-Asn-S5-Tyr-Thr-Met-Val-Leu-His-Lys-NH2!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
Red Line S5 residues for Ring Closing Metathesis 
Blue Line Tyr key residues for interaction between POZ/BTB and Cul3 
 
  
 
3.2.6 Synthesis of Cul3_stapled 
 
The Cul3-stapled, Cul3-stapline peptides and their biotinylated derivatives were 
synthesized by Fmoc solid phase strategy.  
The metathesis reaction was performed on solid phase. The reaction was followed by 
LC/MS on specimens of peptide obtained after cleavage from the resin. 
The identities and the purities (99%) of Cul3-stapled and Cul3-stapline peptides were 
assessed by LC-MS. 
 
 
Table 11 
Peptide Yield (%) Theoretical Mass (Da) Molecular ion peak 
AcCul3-stapled 16,7 2478,2 2477,2 
BiotinylCul3-stapled 15,9 2777,2 2775,8 
AcCul3-stapline 16,3 2506,3 2505,2 
BiotinylCul3-stapline 15,7 2805,3 2804,4  
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Figure 28. LC-MS (A) of AcCul3-stapled and (B) of BiotinCul3-stapled 
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Figure 29. LC-MS (A) of AcCul3-stapline of (B) BiotinCul3-stapline 
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3.2.7 CD Studies 
 
The CD spectra of Cul3-stapled and Cul3-stapline (Figure 30) are almost identical. 
They show two deep minima at ~207-208 nm and 222 nm with similar intensity, a 
cross over at 201 nm, and a maximum at a wavelength lower than 192 nm. The 
general features of the spectra of both peptides are indicative of a good helical 
content. 
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Figure 30. CD spectra ofù Cul3-stapled (red line), Cul3-stapline (green line), Cul3-wt (blue line)  
 
 
The data obtained (Table 12) highlighted that the ratios between the CD signal at 222 
nm and the signal of the other minimum at lower wavelength are 0.98 and 0.95 for 
Cul3-stapled and Cul3-stapline peptides, respectively.  
Noticeably, these values indicate a higher α-helix content of the peptides compared 
to Cul3-wt peptide. 
 
 
Table 12 
Peptide θ222 θmin θ222/θmin θ190 cross 
Cul3-
stapled -8065 -8234 0,979 11675 201 
Cul3-
stapline -7570 -7924 0,955 11314 201  
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3.2.8 ELISA Assay 
 
The assays were performed with biotinylated Cul3-stapled and Cul3-stapline and 
KCTD11-Trx fused protein. Trx protein was used as negative control. 
The trend of binding curve of ELISA assays (Figure 31) displayed that Cul3-stapled 
and Cul3- stapline bind to KCTD11 with similar affinity. 
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Figure 31.	  Binding curves obtained from ELISA assays on the proteins KCTD11 using the 
peptides BiotinCul3-wt  (blue line), BiotinCul3-stapline (yellow line), BiotinCul3-stapled (pink 
line) and BiotinCul3-wt (cyan line) 
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4. CONCLUSION AND FUTURE PERSPECTIVES 
 
The present PhD thesis pertained to the development of new molecules able to 
interfere with relevant cellular activities.  
The starting point was the analysis of molecular features at the basis of some PPI 
involving helical motifs. In particular, the research was focused on the design, the 
synthesis and the biological characterization of peptide molecules mimicking the 
helical surfaces of selected PPI. The design strategy consisted of keeping fixed the 
three dimensional conformation of the residues relevant for the interaction and 
introducing molecular tools to stabilize the helical secondary structure. 
 
Malfunctions in transcriptional regulation are associated with many human diseases 
and there is considerable interest in biotechnological field in developing artificial 
transcription factors that must minimally contain a DBD and a TAD (Figure 32).  
Designing artificial TADs in an efficient and predictable manner has proven difficult 
[60]. Efforts to design artificial TADs are hampered by the fact that TADs interact with 
multiple target proteins as part of their normal function and that there are only a 
limited number of high-resolution structures of TADs in complex with their target 
proteins. 
 
	  
 
Figure 32. Activators in trascription 
 
 
The p53 protein has a fundamental role in cellular survival due to its transcriptional 
activator function. Recent structural studies gave insights into interaction between 
p53 TAD2 and tfb1 subunit of TFIIH and contributed to the understanding of the way 
p53 protein works in transcriptional activation. On the basis of this information, 
peptide molecules mimicking the helical fragment of p53 TAD2, able to bind tfb1 and 
to function as TADs, were designed and synthesized. Our hypothesis was that if we 
could enhance the helical propensity of p53 TAD2, this would yield a more potent 
artificial TAD.  
All the synthesized peptides showed an increased helical content relative to native 
p53-13 peptide as highlighted by CD experiments.  
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ITC experiments showed that E-Cap peptide has a higher binding affinity than other 
peptides and similar to p5325-65 protein. In particular, peptide E-Cap forms a 9-
residue α-helix when in complex with tfb1 and binds along the same interface, as 
evident by NMR spectra. The binding interface is a shallow groove surrounded by 
positively-charged residues that help position the negatively-charged TAD so that its 
hydrophobic residues can participate in a series of van der Waals contacts with 
hydrophobic pockets dispersed along the groove.  
Moreover, the increased in vivo potency of E-Cap relative to the native p53-13 
peptide is directly linked to its enhanced helical stability since both the N-Capping 
motif and the two leucines i, i+3 positions are required for maximal activity.  
The introduction of the hydrophobic interaction on the opposite face to the tfb1 
interacting interface represents a potentially valuable strategy in designing artificial 
TADs with increased in vivo activity. Previous experimental studies with model 
peptides suggested that hydrophobic amino acids with an i, i+4 spacing pattern had a 
slightly higher helix stabilizing effect than those with an i, i +3 spacing pattern, but 
that either pattern can significantly increase the helical propensity of peptides relative 
to alanine. 
In the case of the E-Cap peptide, mutation studies provide evidence that Leu6 can 
participate in i, i+3 interaction with Leu9 and i, i+4 interaction with Trp10 and thus 
both types of interactions are functioning. The fact that the NMR studies of E-Cap in 
complex demonstrates the presence of both the i, i+3 and the i, i+4 interactions 
further confirms the important role of these interactions for the in vitro binding and in 
vivo activity. 
In conclusion, a new peptide with high content of helical conformation was designed 
using only proteinogenic amino acids. This result will be used to develop a new 
interesting biotechnological system such as "programmable ATF", linking obtained 
TAD to new synthetic DBD. 
 
BTB/POZ domain-containing proteins are identified in diverse cellular locations and 
participate in different processes ranging from transcriptional repression/activation to 
cytoskeletal organization. In particular, KCTD are a class of protein containing 
BTB/POZ domain with different biological function as KCTD11 that inhibits tumor 
growth in medulloblastoma.  
The understating of the structural features required for the interaction of the Cul3 with 
KCTDs is an intriguing challenge and is the basis for the future design of molecules 
with agonist/antagonist function for therapeutic applications. 
To achieve this goal the attention was focused on KCTD11 that mediates interaction 
with Cul3 by its POZ/BTB domain at N-terminus. Starting from the proposed model of 
KCTD11-Cul3 interaction, peptide molecules mimicking the helical fragment of Cul3 
49-68, were designed.  
To evaluate the role of some aromatic residues of Cul3 in the interaction with 
KCTD11 two mutant peptides were developed. 
Subsequently, in order to test if the enhance of the helical propensity match with a 
gain in binding affinity, opportunely constrained sequences were designed and 
synthesized. Cul3 stapled peptide, with a hydrocarbon bridge in central position of 
sequence, showed indeed a higher helical structure than the native Cul3-wt peptide. 
Preliminary ELISA assays indicate that both Cul3-wt and Cul3 stapled peptides were 
able to interact with KCTD11.  
Future studies by ITC and NMR will allow the evaluation of the Kd and the molecular 
features governing the interaction with KCTD11. 
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Abstract The cyclic pentapeptide c(RGDfK) is a high
affinity ligand of alphaVbeta3 integrin. It was an analog of
Cilengitide (EMD 121974) developed to be employed as
tracer for cancer diagnosis and therapy by functionalisation of
its Lys side-chain. Solution-phase and solid-phase synthetic
approaches were previously reported. In the attempt to
improve solid-phase synthesis of the cyclopeptide circum-
venting cyclodimerisation reactions, a systematic study of the
synthetic conditions was performed, evaluating and optimis-
ing parameters directly involved in the ring closure step. The
three-dimensional orthogonal solid-phase strategy developed
in this study yields the desired c(RGDfK) peptide with no
cyclodimerisation by-products. The protocols described allow
the modification of the peptide directly on the solid support in
order to obtain novel derivatives for biomedical applications.
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Introduction
RGD-peptides are known to be used for selective targeting
and delivery of drugs to tumour cells. This is due to the
ability of RGD motif to interact with integrin membrane
receptors, such as alphaVbeta3 that is closely associated
with tumour progression, playing an important role in
tumour-induced angiogenesis and metastasis (Brooks et al.
1994a, b; Felding-Habermann et al. 2001; Reinmuth et al.
2003; Zhao et al. 2007; Eliceiri and Cheresh 1999).
Based on the RGD sequence present in the alphaVbeta3
natural ligands, a series of small RGD linear and cyclic
peptides was designed to antagonise the function of this
integrin (Haubner et al. 1997; Zaccaro et al. 2007, 2009)
and, therefore, to promote tumour regression by apoptosis
of angiogenic blood vessels (Brooks et al. 1994a, b) and
to prevent metastases (Clezardin 1998). Kessler and
coworkers, for example, developed a new cyclic peptide
c(RGDfNMeV) (Cilengitide, EMD 121974) (Dechantsreiter
et al. 1999) which entered clinical phase III studies as an
angiogenesis inhibitor for glioblastoma therapy (Eskens
et al. 2003; Haubner et al. 2005; Friess et al. 2006;
Beekman et al. 2006; Nabors et al. 2007; Garanger et al.
2007; MacDonald et al. 2008). Furthermore a large variety
of labeled analogs was developed in order to employ them
as tracers for cancer diagnosis and therapy (Zaccaro et al.
2009). To this end, RGD cyclic peptides carrying a
Lys residue were developed in order to use the Lys side
chain to introduce several tracing molecules. In particular,
c(RGDfK) was synthesised on solid-phase by Kessler and
coworkers (Haubner et al. 1996) by employing an o-chlo-
rotrityl chloride resin and a Fmoc strategy. In this method
the cleavage of the fully protected linear peptide from the
support and cyclisation under high dilution conditions
were described in order to avoid cyclodimerisation and
cyclooligomerisation side reactions. With the aim to cir-
cumvent solubility problems and intermediate purification,
later on, other groups reported the on-resin cyclisation
and lysine functionalisation (Boturyn and Dumy 2001;
McCusker et al. 2002).
It has been described that the cyclisation reaction
represents the key point in the synthesis of constrained head-
to-tail cyclopeptides (Rovero 2000; Lambert et al. 2001)
because of the high tendency of the corresponding linear
precursors to oligomerise (Bodansky 1984). Although solid-
phase cyclisation has represented a step forward respect with
the solution phase counterpart in circumventing cyclodi-
merisation and/or cyclooligomerisation side reactions, it
does not always completely solve the problem.
On the other hand, having a cyclic peptide as single
product of reaction is a desirable goal in order to obtain
more complex systems starting from it directly on solid
phase. Many examples of c(RGDfK) conjugated with
chelator for radionuclides (Zaccaro et al. 2007, 2009) or
functionalised with fluorescent probes (Goldshaid et al.
2010) are reported in literature.
In this paper a systematic study on the synthesis of
c(RGDfK) peptide, by on-resin head-to-tail cyclisation, is
described by using the Fmoc/tBu/OAll three-dimensional
orthogonal solid-phase protection scheme. A comparative
study was undertaken with the aim to evaluate the best
combination of solid support and amino acid protecting
groups that could play an important role in the ring-closure
reaction, avoiding the possible cyclodimerisation side
reaction.
Materials and Methods
Materials
Polypropylene reaction vessels and sintered polyethylene
frits were supplied by Alltech Italia. Wang resin, DPhe
amino acid, MeIm, TFA and scavengers were purchased
from Fluka; NovaSyn TGA and 2-chlorotrityl chloride
resins, coupling reagents and all amino acids were from
Novabiochem. DIPEA was purchased from Romil; piperi-
dine from Biosolve; PhSiH3 and Pd(PPh3)4 from Sigma-
Aldrich.
Peptide Synthesis and Cyclisation Reaction
Assembly of fully protected peptides was carried out
manually in a polypropylene reaction vessel fitted with a
sintered polyethylene frit using the Fmoc/tBu solid-phase
strategy (0.1 mmol). The syntheses were carried out on
Wang, NovaSyn TGA and 2-chlorotrityl chloride resins
(loading 1, 0.26 and 1.3 mmol/g, respectively), using all
standard amino acids except for D-Phe. Resins were swol-
len in DCM for 30 min prior to synthesis. The first amino
acid was bound to the supports carrying hydroxymethyl
groups by treatment with Fmoc–Asp(OAll)–OH (5 equiv)/
MSNT (5 equiv)/MeIm (3.75 equiv) in DCM for 3 h. In the
case of trityl resin, the loading was performed by using 1.2
equiv of Fmoc–Asp(OAll)–OH respect with the resin and 4
equiv of DIPEA relative to the amino acid in DCM for 4 h.
In all cases the yield of the loading after the anchorage of
first amino acid onto the resin was 100%. Fmoc protecting
group was removed by treatment with 30% piperidine in
DMF (3 9 10 min). Coupling reactions of the following
four amino acids (Fmoc–Gly–OH, Fmoc–Arg(Pbf)–OH,
Fmoc–Lys(Mtt)–OH or Fmoc–Lys(ivDde)–OH, Fmoc–
DPhe–OH) were performed by using 10 equiv of Fmoc
protected derivative activated in situ with HBTU (9.8
equiv)/HOBt (9.8 equiv)/DIPEA (20 equiv) in DMF for
30 min. The coupling efficiency was assessed by Kaiser
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test. Each step was followed by resin washings (3 9
5 min). Before the final Fmoc deprotection, selective
a-carboxyl deprotection of the Asp residue from the allyl
group was carried out by treatment of the peptidyl resin
with PhSiH3 (24 equiv)/Pd(PPh3)4 (0.25 equiv) in DCM
(3 9 30 min). The cyclisation between aNH of D-Phe and
aCO of Asp was performed with PyBop (1.5 equiv)/HOBt
(1.5 equiv)/DIPEA (2 equiv) in DMF for 5 h at millimolar
pseudo-dilution.
Finally the peptides were cleaved off the resin and depro-
tected using a mixture of TFA/H2O/EDT/TIS (94:2.5:2.5:1
v/v/v/v) for 3 h. The resins were then filtered, and the white
solid peptides were obtained by precipitation from cold
anhydrous diethyl ether. In the case of the peptides con-
taining Lys residue protected with ivDde, this group was
removed by using a solution of 2% hydrazine in DMF
(10 9 2 min) before cleavage reaction.
Peptide Purification and Characterisation
The crude products were purified by preparative RP-HPLC
on the Shimadzu LC-8A system, equipped with an UV–Vis
detector SPD-10A using a Phenomenex Jupiter Proteo col-
umn (21.2 9 250 mm; 4 lm; 90 A˚) and a linear gradient of
H2O (0.1% TFA)/CH3CN (0.1% TFA) from 5 to 70% of
CH3CN (0.1% TFA) in 30 min at a flow rate of 20 ml/min.
The purified peptides were analysed and characterised by an
ESI-LC-MS instrument (ThermoFinnigan) equipped with a
diode array detector combined with an electronspray ion
source and a quadrupole mass analyzer, using a Phenomenex
Jupiter Proteo column (4.60 9 150 mm; 4 lm; 90 A˚) and
the linear gradient of the preparative scale at a flow rate of
0.8 ml/min. The peptide characterization was also per-
formed by MALDI-TOF spectrometry on a MALDI-TOF
Voyager-DE (Perseptive Biosystem) spectrometer.
Result and Discussion
A systematic study on the synthesis of c(RGDfK), by eval-
uating and optimising parameters directly involved in the
cyclisation step to circumvent cyclodimerisation reactions,
is reported. To this end, six syntheses of RGD-containing
cyclopeptides were performed by using the three-dimen-
sional protection scheme Fmoc/tBu/OAll to allow the
orthogonal deprotection of the C- and N-termini for the
subsequent on-resin head-to-tail cyclisation. Three different
resins were used (Wang (I), NovaSyn TGA (II) and
2-chlorotrityl chloride (III)), for each of them two syntheses
were performed by using Fmoc–Lys(Mtt)–OH and Fmoc–
Lys(ivDde)–OH residues, respectively.
All the peptide syntheses were started by anchoring the
side-chain of an Asp residue to the chosen resin and by
coupling the following amino acids by HBTU/HOBt/DIPEA
procedure according to the Fmoc solid-phase chemistry
(Fig. 1).
Once completed the synthesis, selective a-carboxyl
deprotection of the Asp residue from the allyl group was
carried out with PhSiH3/Pd(PPh3)4 in DCM, and the Fmoc
group of the N-terminal position of the peptide was
removed. Head-to-tail cyclisation between the aNH of
D-Phe and aCO of Asp was performed with PyBop/HOBt/
DIPEA in DMF. Final deprotection and cleavage from the
resin were achieved with TFA and scavengers. Purification
step was realized by RP-HPLC and purity and identity of the
peptides were confirmed by ESI-LC-MS and MALDI-TOF
mass spectrometry.
The first synthesis was performed on Wang resin
employing Fmoc–Lys(Mtt)–OH residue. The crude peptide
obtained gave two chromatographic peaks at RP-HPLC
coupled with ESI-MS (Fig. 2). The largest peak (tR =
11.08 min) corresponded to the desired monomeric form
of c(RGDfK), as shown by the mass ion [M ? H]? at
604.31 m/z (calculated value 603.68 m/z), by the related
diprotonated form [M ? 2H]2? at 303.31 m/z, and by a
species at 1,208.10 m/z that could be assigned to an adduct
formed by two c(RGDfK) molecules (M2) (Fig. 2b). The
second peak at 11.97 min was about 35% of the first, and can
be assigned to the cyclodimerisation product of c(RGDfK)
(2M), as the spectrum indicated the presence of three
mass values potentially corresponding to [2M ? H]? =
1,207.91 m/z (calculated value 1,207.36 m/z), and to the
[2M ? 2H]2? and [2M ? 3H]3? forms at 402.42 and
604.07 m/z, respectively (Fig. 2c). In order to confirm the
hypothesis of the obtainment of dimeric form of c(RGDfK),
MALDI-TOF mass spectra of the purified fractions were
performed (Fig. 3). The spectrum relative to the chromato-
graphic peak at 11.08 min gave the monoprotonated
([M ? H]? = 603.474) and the sodium ([M ? Na]? =
625.476) adduct ions of the cyclomonomeric form (Fig. 3a);
while the one at 11.97 min gave the monoprotonated ion at
1,206.84 m/z, and one and two sodium adduct ions of
the cyclodimeric species at 1,228.66 and 1,250.48 m/z,
respectively (Fig. 3b).
The same result was obtained on Wang resin when
an ivDde-protected Lys residue was used in place of
Fmoc–Lys(Mtt)–OH, and even changing pseudo-dilution
conditions and coupling agents for cyclisation step.
On the basis of this result, c(RGDfK) synthesis using a
different kind of resin was carried on. The resin chosen was
NovaSyn TGA that presents a benzyl alcohol function as
Wang resin with more a PEG spacer. The chromatographic
profile of the crude peptide obtained from this resin, used
together with Mtt-protected Lys, again indicated the pres-
ence of two peaks, as reported above, with the second
about 40% of the first. On the contrary, the combination of
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NovaSyn TGA with ivDde-protected Lys gave only the
desired monomeric c(RGDfK) form as shown by mono-
protonated [M ? H]? = 604.51 m/z and diprotonated
[M ? 2H]2? = 303.60 m/z molecular ions (Fig. 4). The
yield of c(RGDfK) was 66% based on estimated loading of
peptide-resin.
In the attempt to provide a feasible explanation for the
obtained results by using different combinations of resin-
Lys(protecting group), the two syntheses were repeated on
a third kind of resin. The 2-chlorotrityl chloride resin was
chosen with the aim to investigate the consequences of
employing a resin strongly hindered and chemically dif-
ferent respect with those previously used. In this case, the
RP-HPLC analysis of the cyclised product obtained evi-
denced the presence of a single chromatographic peak of
c(RGDfK), both using Lys(Mtt) and Lys(ivDde) residues,
just as for NovaSyn TGA resin combined with Lys(ivDde).
Nevertheless it has to be stressed that this kind of solid
support is not compatible with the use of Lys(Mtt) as the
mild acid deprotection conditions of Mtt group lead to
peptide cleavage from the resin.
Putting together all these data a possible explanation for
the different behaviour observed can benefit of the fol-
lowing considerations. In the process of bending to give
head-to-tail cyclisation, the peptide sequence bumps into a
steric hindrance more or less prominent depending on the
type of resin, Lys protecting group and combination of the
two factors. In more detail, in the case of NovaSyn TGA
resin together with Lys(Mtt) residue, because of the bulky
methyltrityl group, the peptide sequence experiences an
obstacle in the intracyclisation step that leads to a certain
percentage of intercyclic- respect with the intracyclic-
product. On the other side, being ivDde a relatively small
protecting group compared with Mtt, the steric hindrance is
definitely less prominent, therefore the intracyclisation is
the favored reaction.
Interestingly when 2-chlorotrityl chloride is used, the
bulky triphenyl group of the resin totally prevents inter-
cyclisation side reaction both with Mtt and ivDde groups,
giving only the desired cyclomonomeric-product.
Finally about Wang resin, even if this presents chemical
structure similar to NovaSyn TGA that would have
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foreseen an analogous behaviour, the intercyclic side
product is obtained with both Lys-protecting groups. This
could be probably ascribed to the higher loading of Wang
respect with NovaSyn TGA resin that gets peptide chains
closer in the space making the inter-reaction easier to occur.
In conclusion, head-to-tail cyclisation of RGDfK peptide
sequence performed using the combination of NovaSyn
TGA resin with ivDde-protected Lys or 2-chlorotrityl
chloride resin both with ivDde or Mtt-protected Lys gives the
best results in term to prevent cyclodimerisation reaction.
Fig. 2 a RP-HPLC chromatographic profile of crude c(RGDfK) peptide obtained from the synthesis on Wang resin using Mtt as Lys-protecting
group. b and c ESI–MS profiles corresponding to peaks at tR: 11.08 and 11.97 min, respectively
Fig. 3 MALDI-TOF spectra of
purified fractions of c(RGDfK)
peptide corresponding to peaks
at a tR: 11.08 min and
b 11.97 min, respectively
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Concluding Remarks
c(RGDfK) is an alphaVbeta3 integrin ligand very promis-
ing for biotechnological purposes. It is indeed a good tumor
marker and it can be conjugated with a large variety of
chelators for radionuclides or functionalised with fluores-
cent probes for both diagnosis and therapy, through the
lysine side-chain without significant modification of its
binding capacity.
Therefore, the optimisation of condition to cyclise
c(RGDfK) peptide on solid phase allows to obtain a single
compound useful to reduce the following on resin reaction
steps and to increase the final product yield.
In the present paper the conditions to optimize the
cyclisation reaction of c(RGDfK) peptide on solid-phase,
were investigated. The synthesis of c(RGDfK) was
performed using combinations of different resins and
Lys-protecting groups in order to evaluate the role of these
parameters and the influence of their steric hindrance on
the ring closure reaction.
On the basis of the obtained results, it can be concluded
that the use of NovaSyn TGA or 2-chlorotrityl chloride
resins with ivDde-protected Lys residue gives the best
combination of solid support and amino acid protecting
group. This synthetic procedure provides the required
product, usable to carry on further reactions onto the resin,
without any side cyclodimeric adduct.
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Design, synthesis and characterization
of a peptide able to bind proteins of the KCTD
family: implications for KCTD – cullin 3
recognition‡
Luciano Pirone,a,b§ Stefania Correale,a,b§ Ivan de Paola,b Laura Zaccaro,a
Giuseppina De Simone,a Luigi Vitagliano,a Emilia Pedonea∗
and Sonia Di Gaetanoa∗
Pox virus Zinc/Bric-a`-brac, Tramtrack and Broad (POZ/BTB) is a widespread domain detected in proteins involved in a variety
of biological processes. Human genome analyses have unveiled the presence of POZ/BTB domain in a class of proteins (KCTD)
whose role as important players in crucial biological processes is emerging. The development of new molecular entities able
to interact with these proteins and to modulate their activity is a field of relevant interest. By using molecular modeling and
literature mutagenesis analyses, we here designed and characterized a peptide that is able to interact with submicromolar
affinities with two different members (KCTD11 and KCTD5) of this family. This finding suggests that the tetrameric KCTD11 and
the pentameric KCTD5 are endowed with a similar cavity at the subunit–subunit interface deputed to the Cul3 binding, despite
their different oligomeric states. Copyright c© 2011 European Peptide Society and John Wiley & Sons, Ltd.
Keywords: protein–protein recognition; structure–function relationships; ubiquitination; POZ/BTB domains
Introduction
The Pox virus Zinc/Bric-a`-brac, Tramtrack and Broad (POZ/BTB)
domain is a module that has been found in a large number
of functionally unrelated proteins [1–3]. The domain has been
originally identified as a conserved motif present in the Drosophila
melanogaster BTB complex transcription regulators, and in many
POZ finger proteins [1–3]. Proteins containing the POZ/BTB
domain are involved in diversified biological processes, which
include transcription repression [4], cytoskeleton regulation [5],
mediators of oligomerization and gating of ion channels [6]
and protein ubiquitination/degradation [7–9]. It is commonly
assumed that this domain plays a major role in protein–protein
interactions. Structural characterizations of POZ/BTB domains
isolated from different proteins have revealed the occurrence
of variations on a common theme [1]. In all structures of POZ/BTB
domains, so far reported it is possible to identify a common
motif characterized by the presence of a three-stranded β-sheet
and five α-helices [1]. Recent human genome investigations
have highlighted the presence of the POZ/BTB domain in a
new class of human proteins. The POZ/BTB domain of these
proteins share a significant sequence identity (∼30%) with the
tetramerization domain of the K+ voltage-gated channel T1 (T1-
Kv) proteins (http://btb.uhnres.utoronto.ca/index.html). On this
basis, this class of proteins has been denoted as KCTD (K+
channel tetramerization domain containing proteins). Although
KCTD proteins share a common POZ/BTB domain in their
N-terminal regions, they present diversified C-terminal domains
[10]. Although the biological role of these proteins is yet to be
determined, recent investigations suggest that they are involved in
important biological processes. It has been shown that a missense
mutation of KCTD7 is linked to neurodegeneration and progressive
myoclonic epilepsy [11]. Moreover, KCTD15 variants have been
associated with adult obesity risk [12]. Very recently, it has been
shown that KCTD12, previously identified as an important factor
involved in the maturation of ear neurons, along with KCTD8 and
KCTD16, plays a role in the pharmacology and kinetics of the
gamma-aminobutyric acid (GABA(B)) receptor response [13,14].
The two members of the family that have been characterized in
details are KCTD5 and KCTD11. KCTD5, the only member of the
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family whose three-dimensional structure has been determined
experimentally, interacts with human Golgi reassembly stacking
protein 55 (GRASP55) [10,15]. It has also been shown that KCTD5
also interacts with cullin 3 (Cul3) and is potentially involved in the
E3 ubiquitin ligase complex [15].
KCTD11, a tumor suppressor, is an important antagonist of
the Hedgehog pathway which is frequently deleted in human
medulloblastoma [16–19]. Very recent studies have shown that it
is widely downregulated in other human cancers [20]. KCTD11
is involved in the deacetylation and activation of Gli1 and
Gli2, two key transcription factors of Hh signaling. Indeed, Gli1
is deacetylated by histone deacetylase 1 (HDAC1), which is
ubiquitined for degradation by the E3 ubiquitin ligase, formed
by Cul3 and KCTD11 [21].
Taking into account the role played by KCTD in important
biological processes, the development of new molecular entities
able to interact with these proteins and to modulate their activity
is a field of relevant interest. We here report the design and the
characterization of a Cul3-based peptide that is able to interact
either with the pentameric KCTD5 or with the tetrameric KCTD11.
Experimental
Materials
All amino acids, Rink-amide 4-methylbenzhydrylamine (MBHA)
resin, HBTU, HOBt and HATU were purchased from Novabiochem.
DIPEA, TFA, piperidine, N-(+)-biotinyl-6-aminocaproic acid, acetic
anhydride and scavengers were supplied from Fluka. The solvents
used in the synthesis, purification and characterization of the
peptides were from Romil.
Peptide Synthesis
Cul3wt pep and Cul3KK pep derived from Cul3 sequence (see
below) were obtained by Fmoc solid-phase strategy (0.1 mmol).
To mimic the charge status of the fragment within the parent
protein, the N-terminus and the C-terminus of the peptides were
acetylated and amidated, respectively. The syntheses were carried
out with Rink-amide MBHA resin (substitution 0.51 mmol g−1),
using all standard amino acids. Coupling reactions were performed
by using 10 equiv of Fmoc protected amino acids activated in situ
with HBTU (9.8 equiv)/HOBt (9.8 equiv)/DIPEA (20 equiv) in DMF
for 1 h.
Fmoc protecting group was removed by treatment with 30%
piperidine in DMF two times for 10 min. Before the cleavage from
the resin, both peptides were acetylated or biotinylated at N-
terminus to obtain the corresponding derivatives. The acetylation
reaction was carried out two times for 10 min using a solution of
acetic anhydride (0.5 M)/DIPEA (0.015 M)/HOBt (0.125 M) in DMF
(4.7 : 4 : 91.3 v/v/v). Biotinylated peptides were obtained using a
solution of N-(+)-biotinyl-6-aminocaproic acid (2 equiv)/HATU
(1.9 equiv)/DIPEA (4 equiv) in DMF overnight.
All peptides were cleaved off the resin by treatment with a
mixture of TFA/H2O/Ethanedithiol (EDT)/Triisopropylsilane (TIS)
(94 : 2.5 : 2.5 : 1 v/v/v/v) for 2 h at room temperature. The resins
were filtered and the crude peptides were precipitated with diethyl
ether, dissolved in a H2O/CH3CN (1 : 1) solution and lyophilized.
The peptides were purified by preparative RP-HPLC on the
Shimadzu system equipped with a UV-Vis detector SPD10A using
a Phenomenex Jupiter Proteo C12 column (21.2 × 250 mm; 4 µm;
90 Å) and a linear gradient of H2O (0.1% TFA)/CH3CN (0.1% TFA)
from 20 to 70% of CH3CN (0.1% TFA) in 20 min at flow rate of
5 ml/min. The collected fractions containing the peptides were
lyophilized. The identity and purity of the peptides were assessed
by an ESI-LC-MS instrument (ThermoFinnigan, NY, USA) equipped
with a diode array detector combined with an electrospray ion
source and ion trap mass analyzer using a Phenomenex Jupiter
Proteo C12 column (150 × 2 mm; 4 µm; 90 Å´) and a linear gradient
of H2O (0.1% TFA)/CH3CN (0.1% TFA) from 20 to 80% of CH3CN
(0.1% TFA) in 20 min at flow rate of 200 µl/min.
CD Spectroscopy Studies
Far-UV CD spectra were registered in the 190–260 nm range
on a Jasco J-810 spectropolarimeter at 25 ◦C using a quartz
cell with a 0.1-cm path length. The peptides were dissolved in
10 mM phosphate buffer (pH = 7.1). The final concentrations of
Cul3wt pep and Cul3KK pep were 5.56 × 10−5 and 5.05 × 10−5 M,
respectively.
Expression and Purification of POZ/BTB domains of KCTD11
and KCTD5
Expression and purification of the KCTD11 BTB were performed as
described elsewhere [22]. Briefly, the His tag recombinant domain
was expressed as a recombinant fusion protein with thioredoxin
A (TrxA). A homogenous product was obtained upon purification.
The recombinant plasmid containing the POZ/BTB sequence of
KCTD5 was a gift of Prof. Goldstein (Department of Pediatrics and
Institute of Molecular Pediatric Sciences, University of Chicago).
The His-tag recombinant protein was expressed and purified as
already reported [10,22].
ELISA Assays
For ELISA assays, 5 µg/ml streptavidin in phosphate/citrate buffer
pH 5.0 was incubated overnight at 37 ◦C for coating. First, binding
was executed with 0.8 µM biotinylated Cul3 peptide in Phosphate
Buffered Saline (PBS) 1X for 1 h at room temperature. Second,
binding was performed with different concentrations of His-
TrxA/KCTD11 BTB or His/KCTD5 BTB (0.8, 1.5, 3.8, 7.6 and 15.6 µM)
in PBS 1X. His-TrxA was used as negative control in the same
concentrations. As blocking solution 1% BSA, 0.05% Tween-20
in PBS 1X was used for 1 h at room temperature. To reveal
the occurred interaction mouse anti-His monoclonal antibody
was incubated in 1 : 1000 dilution at room temperature for 2 h;
then, horseradish peroxidase-conjugated anti-mouse antibody
(Pierce) was diluted 1 : 10 000 in PBS 1X and incubated at room
temperature for 1 h. The colorimetric reaction has been carried out
with SIGMAFAST OPD reagent (Sigma Aldrich), according to the
manufacturer’s instructions. Finally, a Model 680 Microplate Reader
(Bio-Rad, Hercules, CA-USA) has been used for readings at 490 nm;
data were processed by a Microplate Manager 5.2 program. The
reported data are mean values of triplicate experiments.
Results and Discussion
Design of a Cul3-Based Peptide as a Potential KCTD11 Binder
Previous modeling and mutagenesis studies have provided some
clues on the regions that mediate the recognition between Cul3
and KCTD11 BTB [21,22]. The complex is stabilized by a cluster
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Figure 1. Location of the 49–68 region (red), corresponding to the
sequence of the Cul3wt pep, in the three-dimensional structure of Cul3.
Side chains of the residues Tyr58 and Tyr62 directly involved in KCTD11
are also shown.
Table 1. Analytical data of synthesized peptides obtained by ESI-LC-
MS
Peptide Tr (min)
Theoretical
mass (Da)
Found mass (ESI-MS)
(Da)
Ac-Cul3 wt 15.24 2412.2 2413.1
Biotin-Cul3 wt 15.40 2709.3 2711.8
Ac-Cul3 KK 11.51 2342.2 2343.6
Biotin-Cul3 KK 13.06 2639.4 2640.9
of aromatic residues which include Tyr58, Ty62 and Tyr125 of
the cullin and Phe102 and Tyr103 of KCTD11 BTB. It has been
shown that mutations of these residues inhibit the formation of
the complex. An important role in Cul3-KCTD11 interaction is
played by the helix 55–65 of Cul3 that is tightly bound at the
interface of KCTD11 tetramer. Although other Cul3 residues are
involved in KCTD11 recognition, we focused our attention on the
role played by this region. A Cul3-based peptide as a potential
KCTD11 binder was therefore designed by considering the peptide
NSGLSFEELYRNAYTMVLHK, corresponding to the 49–68 region in
Cul3 sequence (designed as Cul3wt pep hereafter). The location
of this fragment within Cul3 three-dimensional structure is shown
in Figure 1.
Synthesis, Purification, and Characterization of the Cul3-Based
Peptides
To verify the effectiveness of the designed peptide, a biotinylated
form of Cul3wt pep was synthesized on Fmoc solid-phase
and then purified by RP-HPLC. To check the role of aromatic
side chains in Cul3 – KCTD11 recognition, a Cul3wt pep variant
(Cul3KK pep) in which Tyr58 and Tyr62 were substituted with
Lys residues, was also prepared. Cul3KK pep was synthesized and
purified following the same procedures used for Cul3wt pep. The
identities of the obtained compounds were assessed by ESI-LC-MS
(Table 1).
The CD spectra of both peptides, dissolved in a phosphate
buffer (pH = 7.1), show a deep minimum at ∼202–203 nm, a
second minimum at ∼222 nm, a cross over at ∼192–193, and
a maximum at a wavelength lower than 190 nm (Figure 2). The
general features of the spectra are indicative for both peptides of
the presence of a low, but significant, helical secondary structure
content. The ratio between the CD signal at 222 nm and the signal
of the other minimum at lower wavelength, which is often used as
a mean to confirm the presence of helical content [23], is 0.48 and
Figure 2. CD spectra of Cul3wt pep ( ) and Cul3KK pep (- - - - )
registered in phosphate buffer at pH = 7.1. θ is expressed as mean residue
molar ellipticity [(θ )].
Figure 3. Binding curves obtained from ELISA assays on the proteins
KCTD11 BTB (continue line) and KCTD5 BTB (dashed line) using the
peptides Biotin Cul3wt pep (diamond) and Biotin Cul3KK pep (circle).
0.42 for Cul3wt pep and Cul3KK pep, respectively. These values,
although much smaller than those observed for samples with
elevated helical contents (close to the unity), are indicative of the
presence of helical conformations. To quantify the helical content,
we performed spectral deconvolution analysis using CDNN and
CDPRO programs. The estimation of the helical content provided
by these analyses was ∼13% for both peptides.
Cul3 Peptide Interacts with POZ/BTB Domains
with Different Oligomeric Organization
The ability of biotinylated Cul3wt pep to bind the recombinant
KCTD11 BTB domain, expressed as a fused protein with TrxA, was
investigated by ELISA assay, following the procedure illustrated
in the Methods section. The binding of the peptide to TrxA was
monitored as negative control. As shown in Figure 3, the trend
of the binding curve demonstrates that Cul3wt pep specifically
binds KCTD11 BTB with an apparent affinity constant of 0.8 µM.
Similar results were obtained either coating KCTD11 BTB or
the biotinylated peptide through streptavidin. The inability of
the peptide variant Cul3KK pep (Figure 3) to bind KCTD11 BTB
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corroborates the indications provided by the modeling on the
important role of the aromatic residues in the recognition
process.
It has been reported that, in addition to KCTD11, another
member of the KCTD, KCTD5, is able to bind Cul3. Intriguingly, the
BTB domain of KCTD11 and KCTD5 exhibit different oligomeric
states, being KCTD11 and KCTD5 tetrameric and pentameric,
respectively. In this framework, we checked the binding of
Cul3wt pep to KCTD5 BTB. The binding curve (Figure 3) indicates
that the peptide is also able to bind to KCTD5 BTB with an apparent
affinity constant that is similar to that observed for the association
with KCTD11 BTB.
Conclusion
We here show that a rather small peptide derived from a Cul3
fragment is able to interact with BTB domains of KCTD proteins
despite their different oligomeric states. As KCTD are involved
in crucial biological processes, the development of peptides
able to interact with these proteins has important potential
applications. Present findings also suggest strategies for future
peptide optimization. Indeed, we here show that Cul3wt pep only
partially retains the helical state that the fragment assumes in the
parent protein. It is likely that an increase in the helical propensity
of Cul3wt pep variants may be associated with an increased affinity
for KCTD proteins. Several literature successful examples on other
systems conducted using this strategy provide an indirect support
to this approach [24,25].
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Abstract 
Malfunctions in transcriptional regulation are associated with a number of critical human 
diseases. As a result, there is considerable interest in designing artificial transcription activators 
(ATAs) that specifically control genes linked to human diseases. Like native transcriptional 
activator proteins, an ATA must minimally contain a DNA-binding domain (DBD) and a 
transactivation domain (TAD), and although there are several reliable methods for designing 
artificial DBDs, designing artificial TADs has proven difficult. In this manuscript, we present a 
structure-based strategy for designing short peptides containing natural amino acids that function 
as artificial TADs. Using a segment of the TAD of p53 as the scaffolding, modifications are 
introduced to increase the helical propensity of the peptides. The most active artificial TAD, 
termed E-Cap-(LL),  is a 13-mer peptide that contains four key residues from p53, an N-capping 
motif and a dileucine hydrophobic bridge. In vitro analysis demonstrates that E-Cap(LL) interacts 
with several known p53 target proteins, while in vivo studies in a yeast model system show that it 
is a 20-fold more potent transcriptional activator than the native p53-13 peptide. These results 
demonstrate that structure-based design represents a promising approach for developing artificial 
TADs that can be combined with artificial DBDs to create potent and specific ATAs.
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Introduction 
Activation of transcription is regulated by a complex network of macromolecular interactions that 
leads to enhanced rates of gene expression, and one of the key components of this network are 
transcriptional activators 1. Transcriptional activators are proteins minimally composed of a 
DNA-binding domain (DBD) and a transcription activation domain (TAD), and these two 
domains can exist either within the same protein or be assembled through protein-protein 
interactions 1-3. The DBD functions to direct the activator to specific sites on DNA, whereas the 
TAD participates in several protein-protein interactions with multiple components of the 
transcriptional machinery, including nucleosome-remodeling complexes, histone acetyl 
transferases (HATs) and general transcription factors (TFIIB, TBP, TFIIH) 4-12.  
Malfunctions in transcriptional regulation are associated with many human diseases and 
there is considerable interest in developing artificial transcription factors (ATFs) that can either 
activate or repress a specific gene 13-18. Given the recent success using RNAi to repress 
expression of specific genes 19-21, most current efforts are now focused in developing artificial 
transcriptional activators (ATAs). Like their natural counterparts, ATAs must minimally contain 
a DBD and a TAD. The design of artificial DBDs has benefited from the wealth of structural 
information available for DNA and protein:DNA complexes. The most successful examples of 
artificial DBDs include pyrole-imidazole polyamides (PIP) 22-24, peptide nucleic acids (PNA) 25-28 
and engineered zinc-finger proteins 29-31. In contrast to artificial DBDs, designing artificial TADs 
in an efficient and predictable manner has proven difficult 13. Efforts to design artificial TADs are 
hampered by the fact that TADs interact with multiple target proteins as part of their normal 
function 4-12 and that there are only a limited number of high-resolution structures of TADs in 
complex with their target proteins. Structural studies of TADs are limited by the fact that most 
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native TADs are intrinsically unstructured domains that must transition from a disordered to an 
ordered state to bind their targets 32-38. This intrinsic flexibility has made it more difficult to 
crystallize TADs in complexes and this has severely limited the available structural information.  
The most practical solution in designing ATAs has been to attach the sequence from a 
native TAD to the artificial DBD of choice 26,39-42. However, native TADs vary tremendously in 
size and complexity (ranging from 14-300+ amino acids) and often generate variable responses 
when incorporated into ATAs. Attempts to design shorter artificial TADs have generally started 
either by concatenating short sections from native TADs 14,41,43-46 or by screening peptide/peptoid 
libraries 44,45,47-50. Unfortunately, these methods are limited by the fact that it is difficult to 
improve their design in a systematic manner in the absence of structural information. In addition, 
attempts to synthetically prepare small molecules that function as artificial TADs have proven to 
be very challenging 44,51-53. This is also due to the shortage of structural information and the fact 
that TADs often bind over a large surface area when in complex with their partners making it 
difficult to define a scaffold from which to base the design.  
The Herpes Viral protein 16 (VP16) and the human tumour suppressor protein p53 are 
two of the most potent transcriptional activator proteins known, and their TADs share several 
common features 54-56. This includes being very acidic, containing two subdomains 
(p53TAD1/p53TAD2 and VP16N/VP16C), and interacting with many of the same target proteins 
54,55,57. We have previously determined the structures of the second subdomains from the TADs 
of p53 (p53TAD2) and VP16 (VP16C) in complex with the Tfb1 subunit of the general 
transcription factor IIH (TFIIH) 32,33. These structures demonstrated that p53TAD2 and VP16C 
both transition from an unstructured state to form a 9-residue amphipathic α-helix in complex 
with the Pleckstrin Homology domain of Tfb1 (Tfb1PH).  Comparison of the two structures 
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showed that three hydrophobic residues and one acidic residue located at positions four, five, 
seven and eight in the helices of p53 (residues Ile50, Glu51, Trp53 and Phe54) and VP16 
(residues Phe475, Glu476 Met478, Phe479) are crucial to formation of the interface with 
Tfb1PH. Although the three hydrophobic residues are not strictly conserved between p53 and 
VP16, they form similar interactions with Tfb1PH, and this suggests that either of these two 
structures could serve as a general template for the structure-based design of artificial TADs.  
In this paper, we report the design of an artificial TAD [E-Cap(LL)] based on the structure 
TAD of p53 in complex with Tfb1PH. E-Cap (LL) is a 13-residue peptide composed of natural 
amino acids, which preserves the four key residues of p53 that form the interface with Tfb1PH. 
In addition, E-Cap (LL) contains an N-terminal capping motif (N-Cap) and two leucines spaced 
in an i, i+3 manner to increase its helical propensity.  In vitro studies indicate that E-Cap (LL) 
functions like p53TAD2 in a number of binding and competition assays. In addition, E-Cap (LL) 
is an extremely potent in vivo transcriptional activator in yeast. E-Cap-(LL) is the first artificial 
TAD designed based on a known structure of a TAD bound to its target and its potent in vivo 
activity indicates that structure-based design represents a promising approach for developing 
artificial TADs to be used in ATAs. 
  
Page 5 of 35
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  6 
Experimental Procedures 
Chemical peptide synthesis and purification. 
The p53-13, NC15, NC17, A-Cap (LL), E-Cap (LL) and W-Cap (LL) peptide were synthesized 
on solid phase and purified by HPLC (For further details see Supplementary Experimental 
Procedures, Supporting Information). The identity and purity of the peptides were verified by 
LC/MS spectrometry. 
 
Cloning of recombinant proteins for purification. 
The bacterial expressed p53 peptide analogs [E-Cap-(LL), p53-13, p53-13-(LL) and mutants] 
were constructed by inserting the BamHI-EcoR1-digested DNA (IDT) into pGEX-2T plasmid. 
Tfb1PH was cloned as previously described 32. Mutants of Tfb1PH, E-Cap-(LL) and p53-13-(LL) 
were prepared using the QuickChange II site-directed mutagenesis kit (Stratagene). 
 
Protein expression and purification. 
 The p53 peptide analogs and Tfb1PH, were expressed as GST-fusion proteins in E. coli host 
strain TOPP2 and bound to GSH-resin (GE Healthcare) as previously described 32. The resin 
bound protein was incubated overnight with thrombin (Calbiochem). After cleavage, the 
supernatant was purified by FPLC over a Q-Sepharose (p53 analogs) or a SP-Sepharose 
(Tfb1PH) High Performance column.  Uniformly (>98%) 15N-labeled and 15N/13C-labeled 
proteins were prepared in minimal media containing 15NH4Cl with or without 13C6-glucose as the 
sole nitrogen and carbon source. The CBP KIX domain (provided by Alanna Schepartz, Yale 
University, New Haven, CT) was expressed as His-Tag fusion protein in E. Coli host strain BL21 
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(DE3) and purified to homogeneity (See Supplementary Experimental Procedures, 
Supporting Information for details).  
 
Circular Dichroism Studies.  
Circular dichroism (CD) studies were performed with synthetic peptides on a Jasco J-810 
spectropolarimeter at 25°C in 10 mM sodium phosphate (pH=7.1). All peptide concentrations 
were determined by A280. The results are reported as mean residue molar ellipticity [θ]. The 
intensities of [θ] at 215, 207, 190nm, the cross over and the θ222/θ207 ratio are reported for all 
peptides (Supplementary Table 1, Supporting Information). 
 
Isothermal titration calorimetry (ITC) studies. 
The ITC experiments were performed as previously described 32, in 20 mM TRIS (pH=7.5) for 
Tfb1PH, or in 20 mM sodium phosphate (pH=6.5) for the CBP KIX domain. The protein 
concentrations were determined from A280. All titrations were done at least in duplicates and were 
fit to a single binding site mechanism with 1:1 stoichiometry. 
 
Media, plasmids and strains. 
All yeast strains were grown in synthetic complete media (SC; 0,67% yeast nitrogen base w/o 
amino acids, 2% glucose and amino acids drop-out mix) lacking uracil and histidine. The EGY48 
(Mat alpha leu2-3 his3-11,15 trp1-1 ura3-1 6lexAops-LEU2) strain was transformed with the 
LexA operator-Lac-Z fusion plasmid pSH18-34 combined with either pEG202NLS (pEG202 
derivative with SV40 nuclear localization sequence between LexA and polylinker) as a negative 
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control, pSH17-4 (GAL4-activation domain cloned into pEG202 backbone) as a positive control 
or pEG202NLS with LexA fused to the activation domains to be tested 58. 
  
ß-Galactosidase activation assay. 
Liquid ß-galactosidase assays were performed as previously described 58. Results are presented as 
the mean of the percentages of the ß-galactosidase units of the tested peptides on the ß-
galactosidase units of the GAL4 positive control ± standard error of the mean (SEM). Western 
blot analysis was performed with an anti-LexA antibody to verify expression of all LexA-fused 
peptides.  
 
NMR samples. 
For the NMR chemical shift mapping studies with labelled Tfb1PH, the samples consisted of 0.5 
mM 15N-Tfb1PH in 20 mM sodium phophate (pH=6.5), 1 mM EDTA and 90% H2O/10% D2O; 
unlabeled p53 analogs [NC17, NC15, E-Cap-(LL), W-Cap-(LL) or A-Cap-(LL)] were added to a 
final ratio of 1:2. For the chemical shift mapping studies with labeled E-Cap-(LL) peptide, the 
sample consisted of 0.5 mM of 15N-E-Cap (LL) in 20 mM sodium phosphate (pH=6.5), 1 mM 
EDTA and 90% H2O/10% D2O to which unlabeled Tfb1PH was added to a final ratio of 1:2. For 
the competition experiment, an HSQC was first collected with a sample containing 0.8 mM of  
15N-p5340-73 (p53TAD2) in  20 mM sodium phosphate (pH=6.5), 1.0 mM EDTA and 90% 
H2O/10% D2O. Then 1 mM of unlabeled Tfb1PH was added and a second HSQC was collected. 
Finally, 0.8 mM of unlabeled E-Cap-(LL) peptide was added and a third HSQC spectrum was 
recorded. The structural studies of the E-Cap-(LL) peptide in complex with Tfb1PH were 
performed on two samples. The first contained 0.5 mM of 15N-E-Cap-(LL) and 0.5 mM unlabeled 
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Tfb1PH in 20 mM sodium phosphate (pH=6.5), 1 mM EDTA and 90% H2O/10% D2O. The 
second sample contained 0.5 mM 15N/13C-Tfb1PH and 0.5 mM unlabeled E-Cap-(LL) in 20 mM 
sodium phosphate (pH=6.5), 1 mM EDTA. For studies in D2O, the sample was dissolved in 
99.996% D2O.  
 
NMR spectroscopy experiments. 
The NMR experiments were carried out at 295 K on Varian Unity Inova 500, 600 and 800 MHz 
spectrometers. For the chemical shift mapping studies, 2D 1H-15N HSQC were recorded. 
Intramolecular nuclear Overhauser effects (NOEs) for E-Cap (LL) were obtained from 3D 15N-
edited NOESY-HSQC (τm=140 ms) 59 and 2D 13C/15N-{F1/F2}-filtered 1H-1H NOESY (τm=40 
and 100 ms) 60. The NMR data were processed with NMRPipe/NMRDraw  61 and analyzed with 
CcpNmr 62. 
 
Structures calculations. 
The NOE-derived distance restrains were divided into four classes defined as strong (1.8-2.8 Å), 
medium (1.8-3.4 Å), weak (1.8-5.0 Å) and very weak (3.3-6.0 Å). Backbone dihedral angles were 
derived with the program TALOS 63. The structures of E-Cap-(LL) was calculated using the 
program CNS 64, with a combination of torsion angle and Cartesian dynamics 65 and starting from 
an extended structure with standard geometry. The quality of structures was assessed using 
PROCHEK-NMR 66. The figures were generated with the program PyMol (http://www.pymol.org). 
Results 
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p53TAD analogs with an N-Cap and a C-Cap motif. 
Based on the NMR structure of the p53TAD2/Tfb1PH complex 32, we set out to design short 
peptide analogs that mimic both the in vitro binding properties and the in vivo activity of 
p53TAD2.  We hypothesize that peptides analogs with increased helical propensity which, retain 
four key residues (IEXWF) in the α-helix of p53TAD2 (residues 47 to 55 in p53) will mimic 
p53TAD2 and be stronger in vivo activators. In the first approach, capping motifs are introduced 
both at the N- and C-terminus (N-Cap and C-Cap) of the four key residues in two peptides (NC17 
and NC15) (Figure 1A). NC17 consists of 17 residues with an N-Cap and a C-Cap Schellman 
motif which were chosen based on statistical preference 67,68. In NC17, the native GLN at 
position 51 is replaced by a Glu to favor stabilization of an i, i+4 salt bridge with the Lys in the 
C-Cap. NC15 is a 15-residue peptide, which contains the same N-Cap, but its C-Cap Schellman 
motif includes Trp53 and Phe54 from the native p53 sequence. NC15 and NC17 were prepared 
by solid phase peptide synthesis, and their helical character and affinity for Tfb1PH were 
analyzed using circular dichroism (CD) and isothermal calorimetry (ITC), respectively. The CD 
spectra demonstrate a significant increase in helical character for both NC15 and NC17 (θ222/θ207 
ratio of 0.59 and 0.73, respectively) in comparison to p53-13 (θ222/θ207 ratio of 0.23), a control 
peptide corresponding to residues 45 to 57 of the TAD of p53 (Supplementary Table S1, 
Supporting Information). However, ITC experiments indicate that neither NC15 nor NC17 are 
able to bind Tfb1PH under the conditions tested (Figure 2A-B). The absence of binding by ITC 
is further supported by the lack of significant changes in chemical shifts during NMR titration 
experiments with Tfb1PH (data not shown). In comparison, we measure an apparent dissociation 
constant (Kd) of 1.6 ± 0.3 µM for the interaction of p53-13 with Tfb1PH under identical 
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conditions (Figure 2B). Thus, although the addition of an N-Cap and a C-Cap increases the 
helical propensity, both NC15 and NC17 possess significantly lower affinity for Tfb1PH.  
 
p53TAD analogs with an N-Cap and a leucine bridge. 
In the second approach, we combined an N-cap with a hydrophobic bridge involving side chains 
from two leucine residues [(N-Cap-(LL) peptides] (Figure 1B). This approach is similar to the 
one used to develop the VEGF mimetic peptide QK (Figure 1B) 67,69. Three different N-Caps 
were tested and the resulting peptides are referred to as the A-Cap-(LL), E-Cap-(LL) and W-Cap-
(LL) (LTAE, LTEE and LTWE N-Capping residues respectively). The E-Cap-(LL) motif was 
selected based on statistical probability 68, the W-Cap-(LL) was chosen based on homology with 
the QK-peptide 67,69 and the A-Cap-(LL) was chosen based on homology with the N-Cap from 
the helix formed by VP16C 33. The leucines were inserted with an i, i+3 spacing at positions 6 
and 9 so that the hydrophobic interaction would form in the center of the peptide, but on the 
opposite face of the α-helix relative to the Tfb1PH binding interface (Figure 1B). The three 
peptides are all 13-residue long, and CD spectra recorded on the N-Cap (LL) peptides indicate 
that they all possess approximately the same helical character [θ222/θ207 ratios of 0.52, 0.54 and 
0.52 for A-Cap-(LL), E-Cap-(LL) and W-Cap-(LL) respectively], which is significantly higher 
than the p53-13 peptide (Supplementary Table S1, Supporting Information). Next, we 
measured the Kd values of the three peptides for Tfb1PH by ITC. The A-Cap-(LL) and W-Cap-
(LL) have apparent Kd values of 1.3 ± 0.1 µM and 1.9 ± 0.3 µM respectively, which is similar to 
p53-13 (Kd of 1.6 ± 0.3 µM), whereas the E-Cap-(LL) peptide has an apparent Kd of 0.24 ± 0.03 
µM (Figure 2B). Thus, the introduction of a N-Cap in combination with a dileucine bridge 
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improves the helical character of all three peptides and the E-Cap-(LL) peptide binds Tfb1PH 
with the highest affinity.   
 
N-Cap-(LL) analogs and p53TAD2 share a common binding site on Tfb1PH.  
To determine the binding site on Tfb1PH for the N-Cap-(LL) peptides, we performed NMR 
titration and displacement experiments. Addition of unlabeled E-Cap-(LL) to 15N-labeled Tfb1PH 
produces changes in both the 1H and 15N chemical shifts for several signals in the 1H-15N-HSQC 
spectrum of Tfb1PH (Supplementary Figure 1A-B, Supporting Information). Like p53TAD2 
32, the residues that exhibited the most significant changes are located within the strands β5, β6 
and β7 and in the loop between β5 and β6 when mapped on the structure of Tfb1PH (Figure 3A-
B). Similar changes in chemical shifts are also observed in titrations of Tfb1PH with both A-Cap-
(LL) (Supplementary Figure 1C, Supporting Information) and W-Cap-(LL) (Supplementary 
Figure 1D, Supporting Information). In addition, NMR displacement experiments demonstrate 
that p53TAD2 and E-Cap-(LL) (Figure 3C-D) compete for a common binding site on Tfb1PH.  
In a previous study 32, we identified five mutants of Tfb1PH [Tfb1PH (Q49A), Tfb1PH 
(K57E), Tfb1PH (M59A), Tfb1PH (R61E), and Tfb1PH (M88A)] that significantly perturb 
binding to p53TAD2. The five point mutations are located on the surface of Tfb1PH within the 
β5, β6 and β7 strands (Figure 4A) and do not alter the structure of Tfb1PH. By ITC, we are 
unable to detect binding of E-Cap-(LL) to the R61A mutant (Kd ≥ 100 µM) using this assay 
(Figure 4B). In addition, the Q49A and M88A mutants decrease the binding of Tfb1PH to E-
Cap-(LL) by over 20-fold (Kd = 2.4 ± 0.2 µM and 1.9 ± 0.2 µM respectively), whereas the K57E 
and the M59A mutants decrease binding by approximately 10-fold (Kd = 1.0 ± 0.1 µM and 0.9 ± 
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0.09 µM respectively).  These results support that E-Cap-(LL) is forming very similar 
interactions with Tfb1PH as seen with p53TAD2. 
 
E-Cap-(LL) binds to CBP/p300.  
CREB-binding protein (CBP) and p300 (CBP/p300) are two highly homologous HATs that have 
been shown to play an important role in regulating a number of transcriptional activators 
including p53 70,71. Four domains of CBP/p300 (TAZ1/CH1, TAZ2/CH3, KIX and IBiD) have 
been shown to interact with the TAD of p53 and acetylation of p53 by CBP/p300 is essential for 
p53-dependent activation 72,73. ITC studies demonstrate that E-Cap-(LL) is able to interact with 
both the KIX and IBiD domains of CBP/p300 (Kd=3.8 ± 0.8 µM and 0.84 ± 0.12 µM 
respectively; Figure 4C). These results indicate that like the TAD of p53, E-Cap-(LL) is able to 
interact with domains of CBP/p300 .  
 
E-Cap-(LL) is a potent activator in vivo.  
To verify that E-Cap-(LL) activates transcription in vivo, it was fused to the DNA-binding 
domain (DBD) of LexA, and its activation potential was measured in yeast cells. The activity of 
E-Cap-(LL) for the lacZ reporter gene is measured relative to a positive control (Gal4 TAD-
LexA-DBD) whose activity is established as 100 %. In this system, the E-Cap-(LL)-LexA-DBD 
fusion protein activates transcription at 161 ± 9 % of the positive control. In comparison, the 
native p53-13 peptide fused to the LexA-DBD activates transcription at only 8 ± 3 %. Thus, E-
Cap-(LL) is ~20 times more potent than p53-13 as a transcriptional activator in this in vivo 
system (Figure 5). To compare the in vivo activity of the E-Cap-(LL) relative to other known 
artificial TADs, we compared its activity relative to two model artificial TADs, the AH 47 and 
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VP2 45 peptides. The AH-LexA-DBD and VP2-LexA-DBD activates transcription at 
approximately 5 % of the positive control (Figure 5) which is similar to p53-13, but over 30-fold 
less than E-Cap-(LL) .These results strongly support the idea that stabilizing the helical character 
of short analogs of p53TAD2 can lead to a significant enhancement of their in vivo 
transcriptional activity.  
 
The role of leucines for the in vivo activity of the p53TAD analogs.  
To investigate the role that the two leucine residues play in the ability of E-Cap-(LL) to activate 
transcription in vivo, we mutated the leucine residue at position 9 to the native glutamine residue 
found in p53-13 to generate E-Cap-(LQ). This change lowers the in vivo activity to 67 ± 8 % of 
the positive control, and thus E-Cap-(LQ) is ~50% less active than E-Cap-(LL) (161 ± 9 %; 
Figure 5). Next, we inserted two leucine residues at equivalent positions of p53-13 to generate 
p53-13-(LL). The in vivo transcriptional activation of p53-13-(LL) is 10-fold higher than p53-13 
(95 ± 6% versus 8 ± 3%), but 50% less active than E-Cap-(LL) (Figure 5). These results support 
the idea that both the N-Cap motif, and the dileucine-bridge contribute significantly to the in vivo 
transcriptional activity of E-Cap-(LL). 
 
Peptides with leucines in the i, i+4 spacing are less active in vivo 
Experimental and theoretical studies indicate that two hydrophobic amino acids separated by 
either three (i, i+3 spacing pattern) or four residues (i, i+4 spacing pattern) enhance the helical 
propensity of peptides through side-chain interactions 74-78. Given that the insertion of the two 
leucines with an i, i, i+3 spacing pattern enhances the in vivo activation of E-Cap-(LL) and p53-
13-(LL), we tested the role of leucines with an i, i+4 spacing pattern on in vivo activity. Leucine 
Page 14 of 35
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  15 
residues were introduced at positions 4 and 8 in the p53-13 peptide [p53-13-(LL4)] and at 
positions 5 and 9 in the E-Cap-(LL) peptide [E-Cap-(LL4)] (Figure 5). These positions are again 
chosen in an attempt to place the leucine bridge in the center of the peptide, but on the backside 
of the helix relative to the Tfb1PH binding interface. In the yeast activation assay, LexA-p53-13-
(LL4) displays 51 ± 8 % of the activity of GAL4-LexA (Figure 5). This corresponds to a 6-7-
fold increase in activity compared to the native p53-13 (8 ± 3%), but only about half of the 
activity that we observe when the leucines are in the i, i +3 spacing pattern in p53-13-(LL) (95 ± 
6 %).  Similarly, E-Cap-(LL4) displays 60 ± 2 % of the activity of GAL4-LexA, but this 
corresponds to roughly 40% of the activity compared to E-Cap-(LL) (161 ± 9 %). The increased 
in vivo activity observed when two leucines were inserted in either the i, i+3 or i, i+4 spacing 
pattern of p53-13 is consistent with in vitro studies with model peptides showing that both 
spacing patterns are able to increase their helical propensity/stability 74-78.  
 
E-Cap-(LL) forms a helix in complex with Tfb1PH. 
We have previously shown that p53TAD2 transitions from an unstructured state to form a nine-
residue α-helix upon binding to Tfb1PH 32. In this work, we attempted to increase the helical 
propensity of the same region of p53TAD2 by adding an N-Cap and a dileucine bridge.  
Although CD studies indicate that E-Cap-(LL) possesses a higher helical content then p53-13 
(Supplementary Table 1, Supporting Information), NMR experiments with E-Cap-(LL) did 
not show the presence of NOE signals characteristic of an α-helical conformation in the free form 
(Supplementary Figure 2, Supporting Information). Additional NMR studies of E-Cap-(LL) 
in complex with Tfb1PH show that like p53TAD2, it transitions to form a nine-residue α-helix 
from Glu3 to Phe11 (Figure 6A-B and Supplementary Figure 2, Supporting Information). 
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The structure of the E-Cap-(LL) peptide in complex with Tfb1PH is calculated from 105 NOE-
derived distance restraints and 22 dihedral angle restraints. An analysis of the twenty lowest-
energy structures indicates that they have no NOE violation greater than 0.2 Å, no backbone 
dihedral angle violation greater than 2o and low pairwise rmsd values (Table 1). The structure of 
E-Cap-(LL) in complex with Tfb1PH confirms that the side-chains of Leu6 and Leu9 are in close 
proximity to each other, and on the opposite side of the helix relative to the binding interface with 
Tfb1PH (Figure 6C-D). In addition, the side-chain of Leu6 is in position to further stabilize the 
helix through contacts with the aromatic ring of Trp10 in the i+4 position (Figure 6E-F). 
 
Both i, i+3 and i, i+4 side-chain interactions contribute to E-Cap-(LL) activity. 
The NMR studies clearly indicate that Leu6 in the E-Cap-(LL) peptide is in position to enhance 
the stability of the helix through both i, i+3 interactions (L6-L9) and i, i+4 interactions (L6-W10). 
In order to verify this observation, two additional mutants were tested. In p53-13-(LQ), the 
second leucine of p53-13-(LL) is replaced with the native glutamine residue, whereas in the E-
Cap-(DL) the first leucine of E-Cap-(LL) is replaced with the native aspartic acid residue of p53. 
In the yeast activation assay, LexA-p53-13-(LQ) displays 45 ± 8 % of the activity of the control 
(Figure 5). This corresponds to a 5-fold increase in activity compared to the p53-13 peptide (8 ± 
3%), but less than half of the activity we observe when the leucines are in the i, i+3 spacing 
pattern in p53-13-(LL) (95 ± 6 %).  Likewise, E-Cap-(DL) displays 35 ± 4 % of the activity of 
the GAL4-LexA positive control, and this corresponds to roughly one-half of the activity of the 
E-Cap-(LQ) (67 ± 8 %). Consistent with the NMR structure of the E-Cap-(LL) peptide bound to 
Tfb1PH, these results indicate that both i, i+3 interactions (L6-L9) and i, i+4 interactions (L6-
W10) are contributing to the in vivo activity of the p53-13-(LL) and E-Cap-(LL) analogs. 
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Discussion 
ATAs have enormous potential for use as either therapeutic agents for treating human 
diseases or as biological probes for investigating the correlation between aberrant transcription 
and human diseases 13,14. In designing an ATA, the ultimate goal is to construct both the DBD 
and the TAD component as efficiently as possible, while maintaining both specificity and activity 
13. There are now several methods for designing artificial DBDs that depend extensively on the 
availability of high-resolution structural information of protein:DNA complexes 22,23,25-27,29. In 
contrast, there is far less structural information available for TADs in complex with their target 
proteins, and this is mostly due to the fact that TADs are generally intrinsically disordered in their 
free state. Unfortunately, this flexibility and adaptability adds to the complexity of designing 
artificial TADs. Thus, the key step for preparing a minimal artificial TAD is to identify structures 
of TADs in complex with target proteins that could serve as models for the design of artificial 
TADs.  
In this work, we used the structure of the TAD of p53 bound to Tfb1PH as a template for 
designing ATAs 32. Our hypothesis was that if we could enhance the helical propensity of the 
Tfb1PH interacting region from the TAD of p53 this would yield a more potent artificial TAD. 
Like p53, our designed peptide E-Cap-(LL) forms a 9-residue α-helix when in complex with 
Tfb1PH and binds along the same interface. The binding interface is a shallow groove surrounded 
by positively-charged residues that help position the negatively-charged TAD so that its 
hydrophobic residues can participate in a series of van der Waals contacts with hydrophobic 
pockets dispersed along the groove. Superposition of the hydrophobic residues from p53TAD2 
and E-Cap-(LL) peptide when bound to Tfb1PH demonstrates that the residues from the IExWF 
motif [Ile6-Phe11 in E-Cap-(LL)] are located in virtually identical positions (Figure 6D), and E-
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Cap-(LL) appears to make the same contacts with Tfb1PH as p53TAD2. The structure is further 
supported by our ITC results in which mutations of the Tfb1PH residues (Gln49, Lys57, Met59, 
Arg61 and Met88) contributing to the interface with p53TAD2 32 also disrupt binding of the E-
Cap-(LL) peptide (Figure 4A-B).   
The increased in vivo potency of E-Cap-(LL) relative to the native p53-13 peptide appears 
to be directly linked to its enhanced helical stability since both the N-Cap motif and the two 
leucines are required for maximal activity. The introduction of the hydrophobic interaction on the 
face opposite to the Tfb1PH interacting interface represents a potentially valuable strategy in 
designing artificial TADs with increased in vivo activity. Previous experimental studies with 
model peptides suggested that hydrophobic amino acids with an i, i+4 spacing pattern had a 
slightly higher helix stabilizing effect then those with an i, i +3 spacing pattern, but that either 
pattern can significantly increase the helical propensity of peptides relative to alanine 74-77. 
Likewise, Monte Carlo simulations predict that the i, i+3 and i, i+4 spacing of leucines can 
enhance helical stability, but differed from the experimental results by suggesting that i, i+3 
spacing should be more effective 78. In the case of the E-Cap-(LL) peptide, our mutation studies 
provide evidence that Leu6 can participate in i, i+3 interaction with Leu9 and i, i+4 interaction 
with Trp10 and thus both types of interactions are functioning. The fact that the NMR studies of 
E-Cap-(LL) in complex demonstrates the presence of both the i, i+3 and the i, i+4 interactions 
further confirms the important role of these interactions for the in vitro binding and in vivo 
activity. 
The importance of the spacing patterns for bridging interactions has also been observed 
with other helical stabilizing procedures such as stapled peptides and β-peptides 79-81. It is clear 
that the location plays a huge factor when introducing helix-stabilizing modifications, and that 
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structural characterization can aid tremendously in selecting the location. In the case of E-Cap-
(LL), it must still undergo a transition form partially unstructured to the helical conformation that 
binds Tfb1PH. However, the activation energy required for this transition is lowered by the 
presence of the N-Cap and the leucines, and this ultimately leads to a significantly higher level of 
activity in vivo. The key question that still remains is whether we can design a peptide locked in a 
helical conformation that would further enhance the activity in vivo beyond what we observe 
with E-Cap-(LL). To function in vivo TADs must interact with multiple targets using a 
“flycasting” like method 82, and it may be crucial that, like E-Cap-(LL), they retain a minimal 
amount of flexibility to bind optimally to their different targets. Future studies are required to test 
this possibility using more constrained analogs of E-Cap-(LL) and structural studies will be 
crucial to developing and optimizing such constrained analogs. 
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Supplementary Table 1 shows the results of circular dichroism studies. Supplementary Figure 1 
shows HSQC spectra from NMR chemical shift perturbations studies of E-Cap-(LL) and A-Cap-
(LL) with 15N-labeled Tfb1PH. Supplementary Figure 2 shows HSQC spectra from NMR 
chemical shift perturbations studies of Tfb1PH with 15N-labeled E-Cap-(LL). This information is 
available free of charge via the Internet at http://pubs.acs.org. 
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Tables  
Table 1. Structural Statistics for E-Cap-(LL) in Complex with Tfb1PHa 
Restraints used for the structure calculations 
Total number of NOE distances restraints 105 
Short-range (intraresidue) 49 
Medium-range (|i-j|≤4) 56 
Long-range 0 
Number of dihedral angle restraints (φ, ψ) 22 
Structural statistics 
Rms deviations from idealized geometry   
Bonds (Å) 0.0027±0.00007 
Angles (deg) 0.4025±0.0038 
Impropers (deg) 0.231745±0.0111 
Rms deviations from distance restraints (Å) 0.0240±0.0005 
Rms deviations from dihedral restraints (deg) 1.1482±0.015 
Ramachandran statistics (%)b   
Residues in most favored regions 69.2 
Residues in additional allowed regions 30.8 
Residues in generously allowed regions 0 
Residues in disallowed regions 0 
Coordinate precisionc 
Atomic pair wise rmsd (Å)   
Tfb1PH/E-Cap-(LL) complex   
Backbone atoms (C′, Cα, N) 0.50±0.17 
All heavy atoms 1.72±0.32 
 a The 20 conformers with the lowest energies were selected for statistical analysis.  
b Based on PROCHECK-NMR analysis. 
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Figure Legends 
Figure 1. First and second designs of the p53TAD2 mimetics. (A) Sequence alignments of 
p53-13 with the NC15 and the NC17 peptides. The four key residues (IExWF) of the helical 
binding interface of p53TAD2/Tfb1PH complex are highlighted in grey. The residues included in 
N- and C-capping motifs are boxed.  (B) Sequence alignments of p53-13 peptide with the VEGF 
helical analog (QK), A-Cap-(LL), E-Cap-(LL) and W-Cap-(LL). As above, the key residues 
(IExWF) of the helical binding interface of p53TAD2/Tfb1PH complex are highlighted in grey 
and the N- an C-capping motifs are boxed. The two leucine residues forming the bridge with an i, 
i+3 spacing are shown connected by a bridge.  
 
Figure 2. Dissociation constants (Kd) for the interaction between Tfb1PH and the p53TAD2 
analogs. (A) Representative ITC thermagram obtained by successive additions of E-Cap-(LL) 
into a solution of Tfb1PH. (B) Dissociation constants (Kd) for the binding of p53TAD2 peptide 
analogs to Tfb1PH as determined by ITC. All injections fit the single binding site mechanism 
with 1:1 stoichiometry. 
 
Figure 3. E-Cap-(LL) peptide share a common binding site on Tfb1PH with p53TAD2. (A-
B) Ribbon model of the NMR structure of free Tfb1PH 32. Residues that undergo significant 
chemical shift changes in the 1H-15N HSQC spectra of Tfb1PH upon formation of the 
Tfb1PH/p53TAD2 complex are mapped in yellow (A), or upon formation of the Tfb1PH/ E-Cap-
(LL) complex are mapped in red (B). (C) Overlay of a selected region from the two-dimensional 
1H -15N HSQC spectra for a 0.8 mM sample of 15N-labeled p53TAD2 in the free form (black) and 
in the presence of 1.0 mM unlabeled Tfb1PH (red). (D) Overlay of a selected region from the 
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two-dimensional 1H-15N HSQC spectra for a 0.8 mM sample of 15N-labeled p53TAD2 in the free 
form (black), in the presence of 1.0 mM unlabeled Tfb1PH (red), and after addition of 0.8 mM 
unlabeled E-Cap-(LL) peptide (blue). Signals of 15N-labeled p53TAD2 that undergo significant 
changes in 1H- and 15N-chemical shifts upon formation of the complex with Tfb1PH, (C) and that 
return towards their original position following the addition of E-Cap-(LL) peptide (D) are 
indicated by arrows. See Supplementary Figure 1 for spectra of titration of Tfb1PH with E-Cap-
(LL), A-Cap-(LL) and W-Cap-(LL). 
 
Figure 4. Comparison of the dissociation constants (Kd) of E-Cap-(LL) binding to p53 target 
proteins. (A) Ribbon model of the NMR structure of Tfb1PH. The five residues located on the 
surface of Tfb1PH within the β5, β6 and β7 strands that are mutated are highlighted. (B) 
Comparison of the dissociation constants (Kd) for the interaction of the E-Cap-(LL) analog with 
Tfb1PH and the five mutants as determined by ITC measurements. (C) Comparison of the 
dissociation constants (Kd) for the interaction of the E-Cap-(LL) analog with Tfb1PH and the five 
mutants as determined by ITC measurements. 
 
Figure 5. E-Cap-(LL) functions as a potent activation domains in yeast. LexA-peptide fusion 
proteins were co-transformed into yeast with the reporter LexA operator-Lac-Z fusion plasmid 
pSH18-34. Results are presented as the mean of the percentages of the β-galactosidase units of 
the tested fusion proteins on the β-galactosidase units of the LexA-GAL4TAD positive control. 
Error bars represent standard error about the mean of a minimum of three independent 
experiments 
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Figure 6. NMR structure of E-Cap-(LL) peptide in complex with Tfb1PH. (A) Overlay of the 
10 lowest-energy structures of the E-Cap-(LL) peptide in complex with Tfb1PH. The structures 
were superimposed using the backbone atoms C′, Cα, and N. (B) Ribbon model of the 10 lowest 
energy conformers of the E-Cap-(LL) peptide. (C) Overlay of the 10 lowest energy conformers of 
the E-Cap-(LL) peptide showing the relative position of the three hydrophobic residues I7, W10 
and F11. (D) Overlay of residues 45-57 of p53TAD2 (in orange) and the average structure of E-
Cap-(LL) peptide (in blue). The three key hydrophobic residues I50, W53 and F54 of p53TAD2 
are located in similar orientations as I7, W10 and F11 of the E-Cap-(LL) peptide. (E) Ribbon 
model of the 10 lowest energy conformers of the E-Cap-(LL) peptide from the complex with 
Tfb1PH. The side chains of the leucines (L6 and L9) that form the bridge are highlighted. (F) 
Ribbon model of the average structure of the E-Cap-(LL) peptide from the complex with 
Tfb1PH. The side chains of the three hydrophobic residues (I7, W10 and F11) and the leucines 
(L6 and L9) are highlighted to show that they are on opposite faces of the helix. See 
Supplementary Figure 2 for NMR spectra of E-Cap-(LL) in the absence and presence of 
Tfb1PH. 
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p53-13        Ac-LSPDDIEQWFTED-NH2
NC15         Ac-LTPDEFIEQWFKHGI-NH2
NC17         Ac-LTPDEFIEEWFLKDHGI-NH2
QK            Ac-KLTWQELYQLKYKG-NH2
p53-13         Ac-LSPDDIEQWFTED-NH2
A-Cap-(LL)    Ac-LTAEELIELWFTE-NH2
E-Cap-(LL)    Ac-LTEEELIELWFTE-NH2
W-Cap-(LL)    Ac-LTWEELIELWFTE-NH2     
A
B
Figure 1
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BA
Kd values for Tfb1PH 
p53-13 1.6 ± 0.3 μM 
NC15 NB 
NC17 NB 
A-Cap-(LL) 1.3 ± 0.1 μM 
E-Cap-(LL) 0.19 ± 0.03 μM 
W-Cap-(LL) 1.9 ± 0.3 μM 
Figure 2
NB- Kd  > 100 μM 
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Q49
K57
M59
M88
R61
B Kd values of E-Cap-(LL) for Tfb1PH mutants 
Tfb1PH WT 0.09 ± 0.01 μM 
Tfb1PH (Q49A) 2.4 ± 0.2 μM 
Tfb1PH (K57E) 1.0 ± 0.1 μM 
Tfb1PH (M59A) 0.9 ± 0.1 μM 
Tfb1PH (R61A) NB 
Tfb1PH (M88A) 1.9 ± 0.2 μM 
NB- Kd  > 100 μM 
C Kd values of E-Cap-(LL) for CBP/p300 domains 
CBP KIX 3.8 ± 0.8 μM 
CBP IBiD 0.9 ± 0.1 μM 
  
  
Figure 4
A
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